var title_f9_8_9344="Ulnar bowing 2";
var content_f9_8_9344=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Ulnar bowing fracture with radius greenstick fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radius fracture reduced. Notice that ulna is straighter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Schweich, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_8_9344=[""].join("\n");
var outline_f9_8_9344=null;
var title_f9_8_9345="Adrenal hyperplasia MRI";
var content_f9_8_9345=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bilateral adrenal hyperplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T1-weighted MRI through the upper abdomen demonstrates enlargement of both adrenal glands (arrows). This finding could be caused by ACTH-dependent Cushing's syndrome or primary hyperaldosteronism due to adrenal hyperplasia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_8_9345=[""].join("\n");
var outline_f9_8_9345=null;
var title_f9_8_9346="Imperforate hymen 2";
var content_f9_8_9346=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Imperforate hymen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"     </p>",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_8_9346=[""].join("\n");
var outline_f9_8_9346=null;
var title_f9_8_9347="High blood pressure, diet, and weight";
var content_f9_8_9347=[" <h1 id=\"patTopicTitle\">",
"  Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/8/9347/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/8/9347/contributors\" id=\"au4766\">",
"       Norman M Kaplan, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/8/9347/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/8/9347/contributors\" id=\"se5420\">",
"       George L Bakris, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/8/9347/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/8/9347/contributors\" id=\"de7812\">",
"       John P Forman, MD, MSc",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?9/8/9347?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HIGH BLOOD PRESSURE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Hypertension (high blood pressure) is a common condition that can lead to serious complications if untreated. Making dietary changes and losing weight are effective treatments for reducing blood pressure.",
"    </p>",
"    <p>",
"     Other lifestyle changes that can help to reduce blood pressure include stopping smoking, reducing stress, reducing alcohol consumption, and exercising regularly. These changes are effective when used alone, but often have the greatest benefit when used together.",
"    </p>",
"    <p>",
"     An overview of hypertension and a discussion of treatments can be found elsewhere. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"      \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=see_link\">",
"      \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"     </a>",
"     .) More detailed information is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=see_link\">",
"      \"Salt intake, salt restriction, and essential hypertension\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=see_link\">",
"      \"Diet in the treatment and prevention of hypertension\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      DIETARY CHANGES AND BLOOD PRESSURE",
"     </span>",
"    </p>",
"    <p>",
"     Making changes in what you eat can help to control high blood pressure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Reduce sodium",
"     </span>",
"     &nbsp;&mdash;&nbsp;The main source of sodium in the diet is the salt contained in packaged and processed foods and in foods from restaurants. Reducing the amount of sodium you consume can lower blood pressure if you have high or borderline high blood pressure. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=see_link\">",
"      \"Salt intake, salt restriction, and essential hypertension\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The body requires a small amount of sodium in the diet. However, most people consume more sodium than they need. A low sodium diet contains fewer than 2 grams (2,000 milligrams) of sodium each day.",
"    </p>",
"    <p>",
"     A detailed discussion of low sodium diets is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"      \"Patient information: Low sodium diet (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Reduce alcohol",
"     </span>",
"     &nbsp;&mdash;&nbsp;Drinking an excessive amount of alcohol increases your risk of developing high blood pressure. People who have more than two drinks per day have an increased risk of high blood pressure compared to nondrinkers; the risk is greatest when you drink more than five drinks per day.",
"    </p>",
"    <p>",
"     On the other hand, drinking one (for women) or two (for men) alcoholic beverages per day appears to benefit the heart in people greater than 40 years old. This protective effect applies to people with preexisting high blood pressure. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/23/4468?source=see_link\">",
"      \"Patient information: Risks and benefits of alcohol (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Eat more fruits and vegetables",
"     </span>",
"     &nbsp;&mdash;&nbsp;Eating a vegetarian diet may reduce high blood pressure and protect against developing high blood pressure. A strict vegetarian diet may not be necessary; eating more fruits and vegetables and low-fat dairy products may also lower blood pressure. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=see_link\">",
"      \"Diet in the treatment and prevention of hypertension\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Eat more fiber",
"     </span>",
"     &nbsp;&mdash;&nbsp;Eating an increased amount of fiber may decrease blood pressure. The recommended amount of dietary fiber is 20 to 35 grams of fiber per day. Many breakfast cereals are excellent sources of dietary fiber. More information about increasing fiber is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"      \"Patient information: High-fiber diet (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Eat more fish",
"     </span>",
"     &nbsp;&mdash;&nbsp;Eating more fish may help to lower blood pressure, especially when combined with weight loss [",
"     <a class=\"abstract\" href=\"UTD.htm?9/8/9347/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Caffeine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Caffeine may cause a small rise in blood pressure, although this effect is usually temporary. Drinking a moderate amount of caffeine (less than 2 cups of coffee per day) does not increase the risk of high blood pressure in most people (",
"     <a class=\"graphic graphic_table graphicRef58574 \" href=\"UTD.htm?15/56/16268\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      EXERCISE",
"     </span>",
"    </p>",
"    <p>",
"     Regular aerobic exercise (walking, running) for 20 to 30 minutes most days of the week can lower your blood pressure, although the effect is not as pronounced among older adults. To maintain this benefit, you must continue to exercise; stopping exercise will allow your blood pressure to become high again. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"      \"Patient information: Exercise (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      WEIGHT LOSS AND BLOOD PRESSURE",
"     </span>",
"    </p>",
"    <p>",
"     Being overweight or obese increases your risk of having high blood pressure, diabetes, and cardiovascular disease. The definition of overweight and obese are based upon a calculation called body mass index (BMI) (",
"     <a class=\"calc calc_patient\" href=\"UTD.htm?41/23/42366?source=see_link\">",
"      calculator 1",
"     </a>",
"     and",
"     <a class=\"calc calc_patient\" href=\"UTD.htm?36/47/37630?source=see_link\">",
"      calculator 2",
"     </a>",
"     ). You are said to be overweight if your BMI is greater than 25, while a person with a BMI of 30 or greater is said to be obese. People who are overweight or obese can benefit from losing weight.",
"    </p>",
"    <p>",
"     To lose weight you must eat less and exercise more. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"      \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      WHAT IF I STILL HAVE HIGH BLOOD PRESSURE?",
"     </span>",
"    </p>",
"    <p>",
"     If you continue to have high blood pressure despite making changes in your diet, exercising more, and losing weight, you may need a medication to reduce your blood pressure. Medications for high blood pressure are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=see_link\">",
"      \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"      \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H194142412\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H194142419\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=see_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/56/40835?source=see_link\">",
"      Patient information: Controlling your blood pressure through lifestyle (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=see_link\">",
"      Patient information: Diabetes and diet (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/20/37186?source=see_link\">",
"      Patient information: Renovascular hypertension (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/57/27539?source=see_link\">",
"      Patient information: High blood pressure emergencies (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H194142427\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/54/33635?source=see_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/32/37380?source=see_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/23/4468?source=see_link\">",
"      Patient information: Risks and benefits of alcohol (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"      Patient information: High-fiber diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H194142404\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=see_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18068?source=see_link\">",
"      Can therapy be discontinued in well-controlled hypertension?",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37685?source=see_link\">",
"      Cardiovascular risks of hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/55/36728?source=see_link\">",
"      Definition, risk factors, and evaluation of resistant hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=see_link\">",
"      Diet in the treatment and prevention of hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=see_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/422?source=see_link\">",
"      Initial evaluation of the hypertensive adult",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=see_link\">",
"      Overview of hypertension in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23828?source=see_link\">",
"      Patient adherence and the treatment of hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44677?source=see_link\">",
"      Prehypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=see_link\">",
"      Renin-angiotensin system inhibition in the treatment of hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=see_link\">",
"      Salt intake, salt restriction, and essential hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43080?source=see_link\">",
"      Blood pressure measurement in the diagnosis and management of hypertension in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/14/15592?source=see_link\">",
"      Treatment of hypertension in blacks",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17305?source=see_link\">",
"      Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29031?source=see_link\">",
"      Treatment of hypertension in patients with heart failure",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/27/25018?source=see_link\">",
"      Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35256?source=see_link\">",
"      Treatment of resistant hypertension",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=see_link\">",
"      Who should be evaluated for renovascular or other causes of secondary hypertension?",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung &amp; Blood Institute (NHLBI)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"      www.nhlbi.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanheart.org/\">",
"      www.americanheart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?9/8/9347/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?9/8/9347?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9347/abstract/1\">",
"      Mori TA, Burke V, Puddey IB, et al. Effect of fish diets and weight loss on serum leptin concentration in overweight, treated-hypertensive subjects. J Hypertens 2004; 22:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9347/abstract/2\">",
"      Streppel MT, Arends LR, van 't Veer P, et al. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch Intern Med 2005; 165:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9347/abstract/3\">",
"      Noordzij M, Uiterwaal CS, Arends LR, et al. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. J Hypertens 2005; 23:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9347/abstract/4\">",
"      Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9347/abstract/5\">",
"      Elmer PJ, Obarzanek E, Vollmer WM, et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 2006; 144:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9347/abstract/6\">",
"      Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f9_8_9347=[""].join("\n");
var outline_f9_8_9347=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HIGH BLOOD PRESSURE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           DIETARY CHANGES AND BLOOD PRESSURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           EXERCISE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           WEIGHT LOSS AND BLOOD PRESSURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           WHAT IF I STILL HAVE HIGH BLOOD PRESSURE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?15/56/16268\" title=\"table 1\">",
"           Caffeine source amount PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        CALCULATORS",
"       </h1>",
"       <div id=\"relatedCalculators\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"UTD.htm?41/23/42366?source=related_link\" title=\"calculator 1\">",
"           Calculator: Body mass index for adults (Patient information)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"UTD.htm?36/47/37630?source=related_link\" title=\"calculator 2\">",
"           Calculator: Body mass index for adults (Metric, Patient information)",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f9_8_9348="Resection sessile polyp Endosc";
var content_f9_8_9348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Resection of a large sessile colonic polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Sessile polyp in the sigmoid colon measuring approximately 4 cm; (B/C) A monofilament stiff snare is applied tangentially to ensnare a flat portion of the lesion. For complete resection, it is advisable to begin working from a lateral margin of the polyp; (D/E) In repeated maneuvers the polyp is resected in a piecemeal technique. (F) A retrieval net (Roth retrieval net, 2.5 mm sheath diameter, 230 cm sheath length, 2.8 mm diameter, 2.5 cm loop diameter, U.S. Endoscopy Group, Inc., 5976 Heisley Road, Mentor, OH) is used to collect the resected pieces; (G/H) The net can be opened and closed repeatedly without losing the previously collected pieces; (I) Resection site after complete mucosectomy; (J) Clean scar at follow-up three months later.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Uwe Seitz, MD, Sabine Bohnacker, MD, and Nib Soehendra, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_8_9348=[""].join("\n");
var outline_f9_8_9348=null;
var title_f9_8_9349="Lichenoid drug eruption oral";
var content_f9_8_9349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral lichenoid drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    White lesions with a reticular pattern (Wickam striae) can be seen on the tongue and oral mucosa of this patient with oral lichenoid drug eruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_8_9349=[""].join("\n");
var outline_f9_8_9349=null;
var title_f9_8_9350="Pyoderma gangrenosum - Ulcer PI";
var content_f9_8_9350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F85576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F85576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Pyoderma gangrenosum sore",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pyoderma gangrenosum can form a large open sore. The edges can look purple.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_8_9350=[""].join("\n");
var outline_f9_8_9350=null;
var title_f9_8_9351="Subungual hematoma";
var content_f9_8_9351=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Subungual hematoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/8/9351/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/8/9351/contributors\">",
"     Rebecca K Fastle, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/8/9351/contributors\">",
"     Joan Bothner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/8/9351/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/8/9351/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/8/9351/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/8/9351/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/8/9351/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subungual hematoma (blood under the fingernail or toenail), a common childhood injury, is usually caused by a blow to the distal phalanx (eg, crush in a door jamb, stubbing one's toe). The blow causes bleeding of the nail matrix (nail bed) with resultant subungual hematoma formation. Patients complain of throbbing pain and blue-black discoloration under the nail as the hematoma progresses. Pain is relieved immediately for most patients with simple nail trephination.",
"   </p>",
"   <p>",
"    The trephination of subungual hematomas with intact nail fold and minimal nail or digit disruption is discussed here. The evaluation and management of distal phalanx fractures and finger tip injuries are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=see_link\">",
"     \"Distal phalanx fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4472?source=see_link\">",
"     \"Management of fingertip injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subungual hematomas may be simple (ie, the nail and nail fold are intact) or accompanied by significant injuries to the nail fold and digit (eg, fingertip avulsion) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The nail matrix is the tissue under the nail that permits nail growth and migration. Its longitudinal fibers anchor the dermis to the periosteum of the distal phalanx. The matrix begins 7 to 8 mm under the proximal fold, and its distal end is the white crescent called the lunula. Scarring of the matrix, as occurs with nail trauma, can disrupt nail growth and lead to nail deformity or permanent loss of the nail (",
"    <a class=\"graphic graphic_figure graphicRef76994 \" href=\"UTD.htm?24/43/25267\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The richly vascularized nail bed lies directly beneath the plate to provide adherence and support and is the basis of the characteristic pink color. The proximal and lateral nail folds surround the plate on three sides, and the cuticle, an outgrowth of the proximal fold, provides a seal between the fold and the nail plate (",
"    <a class=\"graphic graphic_figure graphicRef76994 \" href=\"UTD.htm?24/43/25267\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When a subungual hematoma occurs, the source of pain is pressure in a contained space pressing against nerve fibers and not from the soft tissue injury or bony injury alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical provider should trephine subungual hematomas that are acute (&lt;24 to 48 hours old) and painful. Beyond 48 hours, most subungual hematomas have clotted and trephination is not effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS AND PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to trephination, the clinician should differentiate subungual hematoma from other conditions that have similar appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/3\">",
"     3",
"    </a>",
"    ]. In many instances, there will be no history of antecedent trauma in these diseases, and the lesions will not be painful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subungual melanoma [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Junctional nevi",
"     </li>",
"     <li>",
"      Splinter hemorrhages &ndash; often associated with infectious endocarditis (",
"      <a class=\"graphic graphic_picture graphicRef72076 \" href=\"UTD.htm?15/63/16369\">",
"       picture 1",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link&amp;anchor=H4#H4\">",
"       \"Diagnostic approach to infective endocarditis\", section on 'Physical examination'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Kaposi sarcoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link\">",
"       \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Subungual keratoacanthoma",
"     </li>",
"     <li>",
"      Subungual epithelioma",
"     </li>",
"     <li>",
"      Subungual glomus tumor",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3424530\">",
"    <span class=\"h2\">",
"     Indications for subspecialty consultation or referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should consult a hand surgeon, if available, if concern related to permanent deformity or loss of finger function exists, including patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Displaced fractures",
"     </li>",
"     <li>",
"      Intraarticular fractures",
"     </li>",
"     <li>",
"      Infected wounds",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The involved digit should be evaluated for neurovascular compromise and inspected for evidence of nail fold disruption, deformity, or avulsion. Specific assessment of the extensor tendon for evidence of tendon disruption at the DIP joint (mallet finger) (",
"    <a class=\"graphic graphic_picture graphicRef77830 \" href=\"UTD.htm?2/51/2879\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66023 \" href=\"UTD.htm?14/24/14721\">",
"     figure 2",
"    </a>",
"    ) should also occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38390?source=see_link\">",
"     \"Extensor tendon injury of the distal interphalangeal joint (mallet finger)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38390?source=see_link&amp;anchor=H4#H4\">",
"     \"Extensor tendon injury of the distal interphalangeal joint (mallet finger)\", section on 'Symptoms and examination findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest obtaining radiographs in all children with large subungual hematomas because associated fractures are common, especially with subungual hematomas that occupy &gt;50 percent of the nail plate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=see_link&amp;anchor=H5#H5\">",
"     \"Distal phalanx fractures\", section on 'Symptoms and physical examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4472?source=see_link&amp;anchor=H452522#H452522\">",
"     \"Management of fingertip injuries\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Patient counseling/Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child or adult with subungual hematoma is typically anxious and in significant pain. The patient and family should receive an explanation of the problem and the planned approach. Anxiety usually recedes once the child's pain is adequately controlled. A child life specialist or other personnel may help with distracting the child during the procedure.",
"   </p>",
"   <p>",
"    In general, the benefit of any of the trephination procedures outweighs the risk. The adverse effects of the technique should be disclosed prior to the initiation of the procedure based on the planned approach including [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood ooze from the site of trephination",
"     </li>",
"     <li>",
"      Pain caused by contact with the nail bed during the procedure",
"     </li>",
"     <li>",
"      Discoloration of the nail lasting up to four weeks",
"     </li>",
"     <li>",
"      Potential loss of the nail despite trephination related to the primary injury",
"     </li>",
"     <li>",
"      Potential for clotting to plug the nail hole, leading to reaccumulation of blood",
"     </li>",
"     <li>",
"      Secondary infection of the nail bed and deeper structures (rare)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should assemble all equipment prior to the procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infectious material precautions: latex-free gloves, eye protection, surgical mask",
"     </li>",
"     <li>",
"      25 gauge or smaller (eg, 27 gauge) needle and 3 to 5 mL syringe for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      injection (if digital nerve block is planned)",
"     </li>",
"     <li>",
"      1 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      WITHOUT epinephrine or 0.25 percent bupivicaine (if digital nerve block is planned) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link\">",
"       \"Infiltration of local anesthetics\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Topical antiseptic (eg, povidone-iodine solution)",
"     </li>",
"     <li>",
"      Sterile gauze",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Trephination using cautery",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrocautery device or carbon laser [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Trephination using a boring technique",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Double bevel 23 gauge or single bevel 18 gauge needle [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/5,8\">",
"       5,8",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp;OR",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insulin syringe needle (29 gauge) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp;OR",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mesoscission device (eg, PathFormer&trade;) (",
"      <a class=\"graphic graphic_picture graphicRef66271 \" href=\"UTD.htm?19/51/20273\">",
"       picture 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3424672\">",
"    <span class=\"h3\">",
"     Choice of device",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that patients with simple subungual hematomas undergo trephination by methods that avoid significant compression of the nail against the nail bed, such as cautery using an electrocautery device or carbon laser, aspiration with an insulin syringe needle (distal nail subungual hematomas only), or a mesoscission device rather than by boring through the nail with a needle. No studies have compared the benefits or risk of the different methods for trephination of subungual hematomas. The clinician should not use a heated paper clip as a cautery device because it requires an open flame to heat the material. In addition, many paper clips are now made of metals (eg, aluminum) that are difficult to heat sufficiently to successfully penetrate the nail [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/5\">",
"     5",
"    </a>",
"    ]. In contrast, electrocautery devices are widely available and effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Analgesia and sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As long as the clinician takes great care not to contact the nail bed during the procedure or to apply excessive pressure to the nail, nail trephination is typically painless because there are no nerve endings in the nail plate, and the hematoma prevents injury to the nail bed (",
"    <a class=\"graphic graphic_figure graphicRef68021 \" href=\"UTD.htm?42/44/43727\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, any pressure may be exquisitely painful in some patients, especially those with concomitant distal phalanx fractures. A digital nerve block may be useful for analgesia in patients with associated distal phalanx fractures or nail matrix (plate) injuries requiring manipulation beyond simple trephination. Otherwise, trephination is a brief procedure and often brings instant pain relief, thus obviating the need for a digital nerve block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=see_link\">",
"     \"Infiltration of local anesthetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, anxiety may be great enough to warrant mild procedural sedation (eg, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ), especially in young children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subungual hematomas with an intact nail fold are treated with nail trephination [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Nail removal is performed when concern exists that nail matrix (plate) laceration has occurred, or in the setting of digital avulsion where subungual sutures are necessary to repair the fingertip or toe tip.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nail trephination",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In selected patients, perform a digital block or sedation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=see_link\">",
"       \"Digital nerve block\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"       \"Procedural sedation in children outside of the operating room\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=see_link\">",
"       \"Procedural sedation in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Restrain the extremity and digit.",
"     </li>",
"     <li>",
"      Clean the nail with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"       povidone iodine",
"      </a>",
"      swabs using sterile technique. Isopropyl alcohol is highly flammable and should be avoided if electrocautery is used.",
"     </li>",
"     <li>",
"      Puncture the nail with a hot metal wire (eg, an electrocautery device [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/6\">",
"       6",
"      </a>",
"      ]) or a carbon dioxide laser (",
"      <a class=\"graphic graphic_figure graphicRef68021 \" href=\"UTD.htm?42/44/43727\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/7\">",
"       7",
"      </a>",
"      ]. Press the device against the nail in the center of the hematoma while avoiding the lunula and its associated nail matrix. Avoid contact with the nail bed. In some patients, the blood may spurt from through the nail under high pressure. The hole should be large enough for continued drainage (three to four millimeters) that may occur for 24 to 36 hours after the injury.",
"     </li>",
"     <li>",
"      Alternatively, trephine using one of the following methods:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Twirl a needle until blood is expressed through the hole [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/8\">",
"       8",
"      </a>",
"      ]. If a small bore needle (eg, 23 gauge) is used, then multiple holes should be placed to reduce the chance of plugging and hematoma reaccumulation. If a large bore needle (eg, 18 gauge) is used, then a single three to four millimeter hole should suffice [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Insert an insulin syringe needle (29 gauge) underneath the nail at the distal hyponychium (",
"      <a class=\"graphic graphic_figure graphicRef76994 \" href=\"UTD.htm?24/43/25267\">",
"       figure 1",
"      </a>",
"      ) and advance it proximally and parallel to the nail plate until the hematoma begins to drain [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/9\">",
"       9",
"      </a>",
"      ]. Apply light pressure to the nail to complete evacuation. This method works especially well for subungual hematomas of the second through fifth toe tips.",
"     </li>",
"     <li>",
"      Using a mesoscission device (eg, PathFormer&trade;) bore multiple holes in the nail over the hematoma (",
"      <a class=\"graphic graphic_picture graphicRef54483 \" href=\"UTD.htm?25/15/25840\">",
"       picture 4",
"      </a>",
"      ). This device uses electrical resistance to determine depth of mechanical boring, thus avoiding inadvertent puncture of the nail bed (",
"      <a class=\"graphic graphic_picture graphicRef66271 \" href=\"UTD.htm?19/51/20273\">",
"       picture 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cover the puncture site with a sterile gauze dressing while the wound continues to drain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nail removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nail removal and primary repair of the laceration are recommended in the event of disruption of the nail matrix (nail fold) or digital (fingertip or toe tip) avulsion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/13\">",
"     13",
"    </a>",
"    ]. However, controversy exists in the literature regarding the need for nail removal, exploration, and suturing of the nail bed when the nail and nail fold are intact.",
"   </p>",
"   <p>",
"    We suggest simple trephination for patients with subungual hematoma in association with an intact nail fold [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some experts recommend removal of the nail with inspection and repair of the nail bed when the hematoma involves greater than 25 to 50 percent of the nail or in the presence of fracture because these findings are associated with nail bed lacerations greater than two to three millimeters [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/13,15,16\">",
"     13,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other experts note that the intact nail acts as a splint to help heal the underlying laceration. As an example, 45 patients with simple subungual hematoma treated with nail trephination (electrocautery) were followed for an average of 10 months in a prospective observational study [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/17\">",
"     17",
"    </a>",
"    ]. No complications (eg, infection, osteomyelitis, nail deformity) were seen, regardless of the size of the hematoma (55 had greater than 50 percent involvement) or presence of fracture (present in 30 percent).",
"   </p>",
"   <p>",
"    Operative and nonoperative repair of subungual hematoma were compared in an observational study of 52 children with intact nails and nail margins [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/1\">",
"     1",
"    </a>",
"    ]. Fractures were present in 12 of 26 children in the operative group and 11 of 26 children in the nonoperative group. None of the fractures were displaced or intraarticular. No differences in outcome occurred between the two groups, regardless of the size of the hematoma, presence of fracture, mechanism of injury, or age. Four patients had transient nail depression or hypertrophy: three in the operative group and one in the nonoperative group.",
"   </p>",
"   <p>",
"    Taken together, these small observational studies fail to show a difference in short or long-term outcomes regardless of whether patients undergo nail removal or simple trephination for subungual hematomas with intact nails and nail folds. Furthermore, nail removal is a painful and time-consuming procedure that typically requires digital anesthetic block and, in young children, procedural sedation. Thus, we suggest simple trephination for patients with subungual hematoma in association with an intact nail fold [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nail removal should occur when a nail laceration threatens the preservation of the nail or digit (nail fold injury with marked laceration of the nail bed, typically in association with a fingertip or toe avulsion). The evaluation and management of fingernail avulsion is discussed in greater detail separately (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4472?source=see_link&amp;anchor=H330664#H330664\">",
"     \"Management of fingertip injuries\", section on 'Fingertip skin avulsion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential complications of a subungual hematoma should be discussed with the patient and his or her parents. They include the possibility of onycholysis (ie, separation of the nail plate from the nail bed), nail deformity, nail loss, and infection. Complications are more likely to occur when care is delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective analysis, 123 patients with 127 subungual hematomas repaired by simple trephination were surveyed 5 to 13 months after their injuries; 74 percent of the patients responded with the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      85 percent reported an excellent or very good outcome.",
"     </li>",
"     <li>",
"      2 percent reported a poor outcome (nail splitting).",
"     </li>",
"     <li>",
"      No correlation was found between outcome and size of the hematoma or the presence of fracture or infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of prophylactic antibiotics does not appear to improve outcomes in patients with subungual hematomas and intact nail folds. For example, an observational study of 47 patients with subungual hematomas who underwent simple trephination, reported no infection, regardless of hematoma size or presence of distal phalanx fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/17\">",
"     17",
"    </a>",
"    ]. None of these patients received prophylactic antibiotics. Thus, we suggest that patients with simple subungual hematomas not receive prophylactic antibiotics after trephination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Distal phalanx fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with subungual hematomas may have associated fractures of the distal phalanx. In one study of 47 patients with subungual hematoma, 32 percent also had distal phalangeal fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/16\">",
"     16",
"    </a>",
"    ]. Fractures were more likely to be present in patients with hematomas involving at least 50 percent of the nail bed than in those involving less (42 versus 0 percent). These findings indicate that radiographs of the distal phalanx are warranted in most patients with subungual hematomas because those injuries will require splinting and, if a displaced fracture is found, subspecialty referral. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=see_link&amp;anchor=H6#H6\">",
"     \"Distal phalanx fractures\", section on 'Radiographic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A distal phalanx fracture associated with a subungual hematoma is an open fracture. The digit should be splinted for comfort. The use of prophylactic antibiotics in healthy patients should not be routine. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the medical provider chooses to use prophylactic antibiotics, then we suggest a first generation cephalosporin (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. However, if community acquired methicillin resistant Staphylococcus aureus (CA-MRSA) is of concern in the provider's region or if the child or family has a recent history of CA-MRSA infection, then antibiotic choice may need to be altered to cover this pathogen (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Infection'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=see_link&amp;anchor=H10#H10\">",
"     \"Distal phalanx fractures\", section on 'Prophylactic antibiotics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=see_link&amp;anchor=H24#H24\">",
"     \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\", section on 'Systemic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;After trephination, the clinician should instruct the patient and family to soak the affected digit in warm, soapy water three times per day for two days, and to keep the area dressed in between soaks.",
"   </p>",
"   <p>",
"    Patients and families should be instructed to return for reevaluation for any of the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reaccumulation of the hematoma with pain",
"     </li>",
"     <li>",
"      Signs of infection (warmth, redness, excessive swelling, fever)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who have subungual hematomas in association with a distal phalanx fracture should receive ice and elevation during the first 24 to 48 hours to reduce soft tissue swelling and oral analgesia (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    10",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum dose: 800 mg).",
"   </p>",
"   <p>",
"    Nondisplaced distal phalanx fractures should be splinted with the DIP joint in extension for three to four weeks. Immobilization past four weeks may lead to excessive joint stiffness and some degree of function loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=see_link&amp;anchor=H8#H8\">",
"     \"Distal phalanx fractures\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Displaced or intraarticular distal phalanx fractures warrant consultation with a hand or orthopedic surgeon at the initial evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=see_link&amp;anchor=H7#H7\">",
"     \"Distal phalanx fractures\", section on 'Indications for surgical referral'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, chronic subungual hematomas may represent child abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9351/abstract/22\">",
"     22",
"    </a>",
"    ]. When suspected, prompt involvement of an experienced child protection team (eg, social worker, nurse, physician with more extensive experience in the management of child abuse), if available, is indicated. In many parts of the world (including the US, UK, and Australia), a mandatory report to appropriate governmental authorities is also required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link&amp;anchor=H3#H3\">",
"     \"Child abuse: Social and medicolegal issues\", section on 'Reporting suspected abuse'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=see_link\">",
"     \"Physical abuse in children: Diagnostic evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=see_link\">",
"     \"Child abuse: Social and medicolegal issues\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3424400\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subungual hematomas (blood under the fingernail or toenail) may be simple (ie, the nail and nail fold are intact) or accompanied by significant injuries to the nail fold and digit (eg, fingertip avulsion) (",
"      <a class=\"graphic graphic_figure graphicRef76994 \" href=\"UTD.htm?24/43/25267\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The medical provider should trephine subungual hematomas that are acute (&lt;24 to 48 hours old) and painful. Beyond 48 hours, most subungual hematomas have clotted and trephination is not effective. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with infected wounds and displaced or intraarticular fractures should be evaluated by a hand surgeon, if available. (See",
"      <a class=\"local\" href=\"#H3424530\">",
"       'Indications for subspecialty consultation or referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The involved digit should have a complete neurovascular exam and specific assessment of the extensor tendon for evidence of tendon disruption at the DIP joint (mallet finger). It should be inspected for evidence of nail fold disruption, deformity, or avulsion. We suggest obtaining radiographs in all patients with large subungual hematomas because associated fractures are common, especially with subungual hematomas that occupy &gt;50 percent of the nail plate. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with simple subungual hematomas undergo trephination by methods that avoid significant compression of the nail against the nail bed such as cautery using an electrocautery device or carbon laser (",
"      <a class=\"graphic graphic_figure graphicRef68021 \" href=\"UTD.htm?42/44/43727\">",
"       figure 3",
"      </a>",
"      ), aspiration with an insulin syringe needle (distal nail subungual hematomas only) (",
"      <a class=\"graphic graphic_figure graphicRef76994 \" href=\"UTD.htm?24/43/25267\">",
"       figure 1",
"      </a>",
"      )or a mesoscission device (",
"      <a class=\"graphic graphic_picture graphicRef54483 \" href=\"UTD.htm?25/15/25840\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef66271 \" href=\"UTD.htm?19/51/20273\">",
"       picture 3",
"      </a>",
"      ) rather than by boring through the nail with a needle (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3424672\">",
"       'Choice of device'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with a subungual hematoma and an intact nail fold undergo simple trephination rather than nail removal and nail bed repair (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Nail removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with simple subungual hematomas not receive prophylactic antibiotics after trephination (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nondisplaced distal phalanx fractures should be splinted with the DIP joint in extension for three to four weeks. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Distal phalanx fractures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/1\">",
"      Roser SE, Gellman H. Comparison of nail bed repair versus nail trephination for subungual hematomas in children. J Hand Surg Am 1999; 24:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/2\">",
"      Ashbell TS, Kleinert HE, Putcha SM, Kutz JE. The deformed finger nail, a frequent result of failure to repair nail bed injuries. J Trauma 1967; 7:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/3\">",
"      Glat PM, Spector JA, Roses DF, et al. The management of pigmented lesions of the nail bed. Ann Plast Surg 1996; 37:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/4\">",
"      Kiryu H. Malignant melanoma in situ arising in the nail unit of a child. J Dermatol 1998; 25:41.",
"     </a>",
"    </li>",
"    <li>",
"     Antevy PM, Saladino RA. Management of finger injuries. In: Textbook of Pediatric Emergency Procedures, 2nd, King C, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. p.939.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/6\">",
"      Palamarchuk HJ, Kerzner M. An improved approach to evacuation of subungual hematoma. J Am Podiatr Med Assoc 1989; 79:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/7\">",
"      Helms A, Brodell RT. Surgical pearl: prompt treatment of subungual hematoma by decompression. J Am Acad Dermatol 2000; 42:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/8\">",
"      Bonisteel PS. Practice tips. Trephining subungual hematomas. Can Fam Physician 2008; 54:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/9\">",
"      Kaya TI, Tursen U, Baz K, Ikizoglu G. Extra-fine insulin syringe needle: an excellent instrument for the evacuation of subungual hematoma. Dermatol Surg 2003; 29:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/10\">",
"      Salter SA, Ciocon DH, Gowrishankar TR, Kimball AB. Controlled nail trephination for subungual hematoma. Am J Emerg Med 2006; 24:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/11\">",
"      Stevenson TR. Fingertip and nailbed injuries. Orthop Clin North Am 1992; 23:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/12\">",
"      Hart RG, Kleinert HE. Fingertip and nail bed injuries. Emerg Med Clin North Am 1993; 11:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/13\">",
"      Zook EG, Guy RJ, Russell RC. A study of nail bed injuries: causes, treatment, and prognosis. J Hand Surg Am 1984; 9:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/14\">",
"      Batrick N, Hashemi K, Freij R. Treatment of uncomplicated subungual haematoma. Emerg Med J 2003; 20:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/15\">",
"      Zacher JB. Management of injuries of the distal phalanx. Surg Clin North Am 1984; 64:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/16\">",
"      Simon RR, Wolgin M. Subungual hematoma: association with occult laceration requiring repair. Am J Emerg Med 1987; 5:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/17\">",
"      Seaberg DC, Angelos WJ, Paris PM. Treatment of subungual hematomas with nail trephination: a prospective study. Am J Emerg Med 1991; 9:209.",
"     </a>",
"    </li>",
"    <li>",
"     Selbst SM, Attia M. Minor trauma lacerations. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1571.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/19\">",
"      Meek S, White M. Subungual haematomas: is simple trephining enough? J Accid Emerg Med 1998; 15:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/20\">",
"      Kensinger DR, Guille JT, Horn BD, Herman MJ. The stubbed great toe: importance of early recognition and treatment of open fractures of the distal phalanx. J Pediatr Orthop 2001; 21:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/21\">",
"      Fox IM. Osteomyelitis of the distal phalanx following trauma to the nail. A case report. J Am Podiatr Med Assoc 1992; 82:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9351/abstract/22\">",
"      Gavin LA, Lanz MJ, Leung DY, Roesler TA. Chronic subungual hematomas: a presumed immunologic puzzle resolved with a diagnosis of child abuse. Arch Pediatr Adolesc Med 1997; 151:103.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6335 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-510B38B3F6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_8_9351=[""].join("\n");
var outline_f9_8_9351=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3424400\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CONTRAINDICATIONS AND PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3424530\">",
"      Indications for subspecialty consultation or referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Patient counseling/Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Materials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Trephination using cautery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Trephination using a boring technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3424672\">",
"      - Choice of device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Analgesia and sedation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nail trephination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nail removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Distal phalanx fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3424400\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6335\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6335|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/43/25267\" title=\"figure 1\">",
"      Nail anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/24/14721\" title=\"figure 2\">",
"      Mallet finger mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/44/43727\" title=\"figure 3\">",
"      Nail trephination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6335|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/63/16369\" title=\"picture 1\">",
"      Splinter hemorrhages in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/51/2879\" title=\"picture 2\">",
"      Mallet finger photo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/51/20273\" title=\"picture 3\">",
"      Mesoscissioning procedure 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/15/25840\" title=\"picture 4\">",
"      Mesoscissioning procedure 1",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/5/35927?source=related_link\">",
"      Child abuse: Social and medicolegal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=related_link\">",
"      Digital nerve block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=related_link\">",
"      Distal phalanx fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=related_link\">",
"      Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38390?source=related_link\">",
"      Extensor tendon injury of the distal interphalangeal joint (mallet finger)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4472?source=related_link\">",
"      Management of fingertip injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24890?source=related_link\">",
"      Physical abuse in children: Diagnostic evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_8_9352="Etravirine: Pediatric drug information";
var content_f9_8_9352=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Etravirine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"    see \"Etravirine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/56/10117?source=see_link\">",
"    see \"Etravirine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5606106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Intelence&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5994283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Intelence&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F7291409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F7291421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"      see \"Etravirine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HIV infection, treatment: Note:",
"     </b>",
"     Use in combination with other antiretroviral agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &lt;6 years or pediatric patients &lt;16 kg: Not recommended for use; has not been evaluated; no dosing recommendations available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;6 years and Adolescents: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ge;16 kg to &lt;20 kg: 100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ge;20 kg to &lt;25 kg: 125 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ge;25 kg to &lt;30 kg: 150 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ge;30 kg: 200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: Oral: 200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Children, Adolescents, and Adults: No dosage adjustments required (DHHS [pediatric], 2012 and [adult], 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild to moderate impairment (Child-Pugh class A or B): Children, Adolescents, and Adults: No dosage adjustments required (DHHS [pediatric], 2012 and [adult], 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe impairment (Child-Pugh class C): Adolescents and Adults: No dosage adjustments required (DHHS [adult], 2013).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5605757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intelence&reg;: 25 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intelence&reg;: 100 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5605504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7291422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer after meals. Swallow tablet whole  with water; do not chew. If unable to swallow tablets, may disperse tablets in 5 mL water (enough to cover tablets), stir well (until milky appearance), add additional water (or may add milk or orange juice), and drink immediately. Rinse glass several times (with water, milk, or orange juice) and swallow entire contents to ensure administration of full dose. Do not use grapefruit juice, carbonated beverages, or warm (&gt;40&deg;C) drinks (including warm water).",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F7291418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Store in the original bottle; keep tightly closed. Protect from moisture and do not remove the desiccant pouches.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7291410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV-1 infection in combination with other antiretroviral agents (FDA approved in ages &ge;6 years weighing at least 16 kg and adults);",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of",
"     <b>",
"      three",
"     </b>",
"     antiretroviral agents are strongly recommended.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13811173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Etravirine [U.S. and multiple international markets] may be confused with ethaverine [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F5605593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Cholesterol (total) increased, hyperglycemia, LDL increased, triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Amylase increased, diarrhea (children and adolescents), nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Amnesia, anemia (including hemolytic), angina, angioedema, anorexia, atrial fibrillation, diabetes mellitus, drug rash with eosinophilia and systemic symptoms (DRESS), erythema multiforme, GERD, gynecomastia, hemorrhagic stroke, hematemesis, hepatic failure, hepatic steatosis, hepatitis, hepatomegaly, hypersensitivity reaction, hypersomnia, hypoesthesia, immune reconstitution syndrome, insomnia, lipohypertrophy/dystrophy, MI, pancreatitis, paresthesia, renal failure, rhabdomyolysis, seizure, Stevens-Johnson syndrome, syncope, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7291413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to etravirine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F15678859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with severe hepatic dysfunction (Child-Pugh class C); use has not been evaluated. Cross-resistance with other non-nucleoside reverse transcriptase inhibitors may occur. Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents (causal relationship not established).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Immune reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents; this syndrome may require further patient assessment and therapy. Autoimmune disorders (eg, Grave&rsquo;s disease, Guillain-Barr&eacute; syndrome, and polymyositis) have been reported in patients experiencing immune reconstitution; time to onset is variable and may occur many months after antiretroviral treatment is initiated.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7291414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe, life-threatening, and fatal cases of skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and hypersensitivity reactions accompanied by rash, constitutional symptoms, and occasional organ dysfunction including hepatic failure have been reported; discontinue immediately with signs or symptoms of severe skin reaction or hypersensitivity including rash, fever, blistering, oral lesions, conjunctivitis, facial edema, muscle or joint aches, general malaise, fatigue, hepatitis, eosinophilia, or angioedema and monitor clinical status including liver function; initiate appropriate therapy. Rash, including serious (Grade 3 or 4) events and discontinuations, were more frequently observed in female subjects compared to male subjects.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Rash is more common and severe in pediatric patients (6 years to &lt;18 years) than in adults; usually described as pruritic, maculopapular skin eruptions (incidence: Pediatric patients: 15%, adults 10%). In pediatric patients, rashes usually appeared within 14 days of starting therapy and generally resolved within a week. Discontinue etravirine if severe rash (involving blistering, desquamation, mucosal involvement, ulceration, or fever) occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Etravirine is a mixed inducer/inhibitor of CYP450 enzymes and numerous drug interactions occur. Due to potential serious and/or life-threatening drug interactions, certain drugs must be avoided; other drug interactions may require dosage adjustment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Resistance emerges rapidly if administered as monotherapy; always use etravirine in combination with at least two other antiretroviral agents; do not add etravirine as a single agent to antiretroviral regimens that are failing; initiate in combination with at least one other antiretroviral agent to which the patient is naive.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5605666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP2C9 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (moderate), CYP2C9 (moderate);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5605665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Etravirine may decrease the serum concentration of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Etravirine may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Etravirine.  Management: Monitor for increased effects/toxicity of etravirine.  Antifungal dose adjustment may be needed for ketoconazole, itraconazole, or posaconazole but specific dosing guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: Etravirine may decrease serum concentrations of the active metabolite(s) of Artemether. Specifically, concentrations of dihydroartemisinin may be decreased. Artemether may increase the serum concentration of Etravirine. Etravirine may increase the serum concentration of Artemether.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Etravirine. Etravirine may decrease the serum concentration of Atazanavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bepridil [Off Market]: Etravirine may decrease the serum concentration of Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Boceprevir.  Management: Avoid strong CYP3A4 inducers with boceprevir when possible, and closely monitor response to boceprevir if such a combination cannot be avoided. Carbamazepine, phenytoin, phenobarbital, rifampin, and St. John's wort are considered contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: Etravirine may decrease the serum concentration of Buprenorphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazepam: Etravirine may decrease the serum concentration of Diazepam. Etravirine may increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest.  Management: Avoid use of dienogest for contraception when using medications that induce CYP3A4 and for at least 28 days after discontinuation of a CYP3A4 inducer.  An alternative form of contraception should be used during this time.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Etravirine may increase the serum concentration of Digoxin.  Management: Monitor serum digoxin concentrations and adjust dose as needed. In patients initiating a regimen of digoxin with etravirine, digoxin should be initiated at the lowest dose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Etravirine may decrease the serum concentration of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Etravirine may decrease the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Etravirine may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may increase.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Etravirine may decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin, lovastatin and simvastatin. Conversely, levels of fluvastatin may be increased.  Management: Dose adjustment of the HMG-CoA reductase inhibitor may be warranted. No interaction is expected with rosuvastatin, pravastatin, or pitavastatin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pitavastatin; Pravastatin; Rosuvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Etravirine may decrease the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: Etravirine may decrease the serum concentration of Macrolide Antibiotics. Clarithromycin AUC is reduced and levels of the active metabolite (14-hydroxy-clarithromycin) are modestly increased.  Management: For the treatment of",
"     <i>",
"      Mycobacterium avium",
"     </i>",
"     complex, consider changing to alternative agent, such as azithromycin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Etravirine may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: Etravirine may decrease the serum concentration of Mexiletine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PACLitaxel: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the metabolism of PACLitaxel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Etravirine. Management: The manufacturer of etravirine states these drugs should not be used in combination",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: Etravirine may decrease the serum concentration of Phosphodiesterase 5 Inhibitors.  Management: No empiric dosage adjustments are recommended with concomitant therapy; however, dose of the phosphodiesterase inhibitor may need to be altered based on clinical response.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Etravirine may decrease the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Etravirine may increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir, saquinavir, and lopinavir (with low-dose ritonavir).  Management: Low-dose ritonavir boosting must be used when any protease inhibitor is used with etravirine.  Avoid use of etravirine in combination with atazanavir, fosamprenavir, full-dose ritonavir (600 mg twice daily), or tipranavir.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atazanavir; Fosamprenavir; Ritonavir; Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Etravirine may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reverse Transcriptase Inhibitors (Non-Nucleoside): May decrease the serum concentration of Etravirine. This has been observed with the NNRTIs efavirenz and nevirapine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Etravirine. This has been observed with delavirdine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: May decrease the serum concentration of Etravirine. Management: Avoid concomitant use with rifabutin if a protease inhibitor/ritonavir combination is also used.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Etravirine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Rilpivirine. This mechanism applies to coadministration of delavirdine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Rilpivirine. This mechanism applies to coadministration of efavirenz, etravirine, and nevirapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Specifically, St. Johns Wort may increase the metabolism of Reverse Transcriptase Inhibitors (Non-Nucleoside).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Etravirine may decrease the serum concentration of Telaprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F7291417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Etravirine AUC is decreased ~50% when administered while fasting.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5605508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5605509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been noted in animal reproduction studies. Etravirine crosses the placenta. Based on limited data, dose adjustments are not needed in pregnant women. However, because available data in pregnant women are insufficient, the DHHS Perinatal HIV Guidelines do not recommend use in antiretroviral-naive women unless other alternatives are not available. Hypersensitivity reactions (including hepatic toxicity and rash) are more common in women on NNRTI therapy; it is not known if pregnancy increases this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7291443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Monitor CD4 percentage (if &lt;5 years of age) or CD4 count (if &ge;5 years of age) at least every 3-4 months (DHHS [pediatric], 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prior to initiation of therapy: Genotypic resistance testing, CD4, viral load, CBC with differential, LFTs, BUN, creatinine; at initiation and with any change in treatment regimen:  CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, BUN, creatinine, albumin, total protein, lipid panel, CD4, and viral load. After 4-8 weeks of therapy: CBC with differential, viral load; then every 3-4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, and viral load. Albumin, total protein, calcium, phosphate, lipid panel, and urinalysis every 6-12 months (DHHS [pediatric], 2012).  Monitor for signs of opportunistic infections, skin rash, or hypersensitivity.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F15681712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Monitoring of etravirine levels is not routinely recommended. Insufficient data are available to recommend a target trough concentration (DHHS [adult], 2013).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7291419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A non-nucleoside reverse transcriptase inhibitor which specifically binds to HIV-1 reverse transcriptase blocking the RNA-dependent and DNA-dependent DNA polymerase activities, including HIV-1 replication",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7291420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Pharmacokinetic data suggests that with comparable dosing, exposure in pediatric patients &ge;6 years is similar to adult patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Decreased under fasting conditions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~99.9%; primarily to albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, primarily by CYP3A4, 2C9, and 2C19; major metabolites exhibit ~10% of parent drug activity against wild-type HIV",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 41 hours &plusmn; 20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 2.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Feces (up to 86% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: Due to extensive protein binding, significant removal by hemodialysis or peritoneal dialysis is unlikely",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F7291444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/56/10117?source=see_link\">",
"      see \"Etravirine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Etravirine is not a cure for HIV, nor has it been found to reduce transmission of HIV; use appropriate precautions to prevent spread to other persons. Must be taken as one part of a multidrug combination; take exactly as directed. Take after meals. Frequent blood tests may be required. May experience nausea, vomiting, or changes in body fat (increased in upper back, neck, breasts, and around trunk; decreased from extremities and face). Report immediately any sign of skin rash or allergic reaction.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aberg JA, Kaplan JE, Libman H, et al, \"Primary Care Guidelines for the Management of Persons Infected With Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 49(5):651-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/8/9352/abstract-text/19640227/pubmed\" id=\"19640227\" target=\"_blank\">",
"        19640227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" November 5, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87706 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_8_9352=[""].join("\n");
var outline_f9_8_9352=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5606106\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5994283\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7291409\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7291421\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605757\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605504\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7291422\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7291418\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7291410\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13811173\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605593\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7291413\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15678859\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7291414\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605666\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605665\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7291417\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605508\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605509\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7291443\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15681712\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7291419\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7291420\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7291444\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87706\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/87706|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=related_link\">",
"      Etravirine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/56/10117?source=related_link\">",
"      Etravirine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_8_9353="Non-iron pharmacologic adjuvants to erythropoiesis stimulating agent therapy in dialysis patients";
var content_f9_8_9353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Non-iron pharmacologic adjuvants to erythropoiesis stimulating agent therapy in dialysis patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/8/9353/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/8/9353/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/8/9353/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/8/9353/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/8/9353/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/8/9353/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/8/9353/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    (rHuEPO; Epoetin) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"     darbepoetin alfa",
"    </a>",
"    is effective in treating anemia in the vast majority of patients on dialysis. However, some patients are relatively resistant or \"hyporesponsive\" to epoetin. This may be defined as the failure to reach target hemoglobin (Hgb) or hematocrit (Hct) levels despite epoetin doses greater than 300 to 450 international",
"    <span class=\"nowrap\">",
"     units/kg/week",
"    </span>",
"    in the absence of iron deficiency (and equivalent darbepoetin) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Iron deficiency, either absolute or functional, and inflammation are the most common causes of an inadequate response to epoetin therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=see_link\">",
"     \"Inflammation in renal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with chronic kidney disease (CKD), absolute iron deficiency is characterized by a serum ferritin concentration less than 100",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and transferrin saturation (TSAT) less than 20 percent. Functional iron deficiency is characterized by ferritin levels that are generally above 500",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    but with TSAT that is often less than 20 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28005?source=see_link\">",
"     \"Diagnosis of iron deficiency in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=see_link\">",
"     \"Use of iron preparations in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar iron indices (elevated serum ferritin with a low TSAT) are often also seen in patients with inflammatory processes associated with epoetin hyporesponsiveness. In such patients, other laboratory markers associated with the acute phase response that may be clinically useful include low (or falling) serum albumin levels and elevated level of C-reactive protein (CRP). While a CRP level diagnostic of inflammation-related epoetin hyporesponsiveness in dialysis patients has not been established, a level above 20",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    would be very suggestive of an active, underlying inflammatory process [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=see_link\">",
"     \"Inflammation in renal insufficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will address pharmacologic therapies other than iron that have been investigated as adjuvants to erythropoiesis-stimulating agents (ESAs) therapy to either address epoetin hyporesponsiveness or otherwise enhance the response to epoetin and reduce its economic impact. The effect of dialysis adequacy, hemodialysis membrane composition, and different dialysis modalities will not be discussed herein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of non-iron pharmacologic agents have been evaluated as adjuvants to erythropoiesis stimulating agents (ESA). Although some have been suggested for use in patients who are \"hyporesponsive\" to epoetin, these agents have not been studied in hyporesponsive patients for the most part. These agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    , ascorbic acid, androgens,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    , statins, and others.",
"   </p>",
"   <p>",
"    The following sections will review the evidence concerning efficacy and toxicity of these agents as adjuvants to epoetin therapy. The use of these agents as monotherapy in patients not receiving epoetin is not discussed herein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     L-CARNITINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     Carnitine",
"    </a>",
"    is important in energy metabolism, as it is required for the transport of long-chain fatty acids into mitochondria. Carnitine is also thought to be involved in the conversion of acyl CoA, which is toxic and accumulates in renal failure, to the less toxic acyl carnitine.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     Carnitine",
"    </a>",
"    metabolism is disturbed in many patients with decreased glomerular filtration rate and on dialysis, with alterations in total, free, and acyl carnitine plasma levels. Loss of carnitine through dialysis has been suggested to result in a carnitine deficient state in hemodialysis patients. As a result,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    has been used therapeutically in dialysis patients for the treatment of anemia with and without concomitant epoetin, and other conditions. Nocturnal dialysis may ameliorate some of the disturbances of carnitine metabolism seen in patients on conventional dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exact mechanism by which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    supplementation might improve anemia in patients with kidney disease is unknown.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    reportedly increased formation of colony forming unit-erythroid (CFU-E) colonies in cell cultures of mouse bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/6\">",
"     6",
"    </a>",
"    ]. Whether this is clinically important is unknown. Alterations in the red blood cell phospholipid membrane and effects on red blood cell deformability and osmotic fragility, leading to increased cell survival has been proposed. However, there is not yet convincing evidence about the importance of these effects in dialysis patients.",
"   </p>",
"   <p>",
"    Issues surrounding its use in conditions other than anemia are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14200?source=see_link\">",
"     \"Carnitine metabolism in renal disease and dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in plasma",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    levels are not consistently predictive of clinical response to carnitine supplementation. There is an extensive literature of anecdotal reports, small case series, and uncontrolled studies suggesting that intravenous or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    increases hemoglobin (Hgb) levels",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduces ESA requirements in both adults and children with renal failure, with most of the studies done in patients on hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have only been a few randomized, controlled trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    in ESA-treated patients in which anemia-related outcomes were the primary study end-points [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Results have been conflicting and",
"    <strong>",
"     none",
"    </strong>",
"    of the studies were conducted in ESA hyporesponsive patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter randomized, double-blinded study, 92 hemodialysis patients were randomly assigned to placebo or to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      (1 g per session) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/12\">",
"       12",
"      </a>",
"      ]. At one year, the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      concentrations increased from 79 to 258",
"      <span class=\"nowrap\">",
"       &micro;mol/L",
"      </span>",
"      in the L-carnitine group whereas it decreased from 68 to 53",
"      <span class=\"nowrap\">",
"       &micro;mol/L",
"      </span>",
"      in the placebo group. Despite the change in the carnitine concentration, there was no difference between groups in the ESA resistance index (defined as mean weekly ESA dose [calculated from monthly ESA dose per kg body weight] divided by the hemoglobin).",
"     </li>",
"     <li>",
"      In one prospective randomized double-blind study in hemodialysis patients, treatment with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      at a dose of 1 gm at each dialysis treatment for six months was associated with a 37 percent reduction in ESA dose, while Hct was maintained unchanged [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/9\">",
"       9",
"      </a>",
"      ]. Neither Hct nor ESA dose changed in the control group. A fall in ESA dose was observed in seven of 13 treated patients, all of whom showed the maximal benefit in terms of ESA dose reduction by four months.",
"     </li>",
"     <li>",
"      In a second study of similar design,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      treatment was not associated with a reduction in ESA dose or change in Hct over a six month treatment period [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/10\">",
"       10",
"      </a>",
"      ]. In a post-hoc analysis of patients over the age of 65 years, there was a nonsignificant trend towards a lower ESA dose in treated patients but not controls.",
"     </li>",
"     <li>",
"      In a third study, patients were randomly assigned to receive either 5 or 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      at each dialysis treatment for eight months, with supplemental IV iron at each treatment for the first four months (control patients received the same iron regimen without L-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/11\">",
"       11",
"      </a>",
"      ]. ESA doses did not change over the first four months of the study in the treated group, while no data are provided on the second four months of treatment. Eight of 19 L-carnitine-treated patients were described as responders, based on an unspecified reduction in ESA dose, with a reduction in the mean weekly dose by 37 percent in these patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mean erythropoietin resistance index improved in two of these controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/9,11\">",
"     9,11",
"    </a>",
"    ] but not in the other [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/10\">",
"     10",
"    </a>",
"    ]. In two additional randomized, controlled trials in which anemia and ESA dosing were not primary endpoints, IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    was not associated with significant changes in Hgb or ESA dose from baseline or compared to a control group [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2002 meta-analysis evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    supplementation in lowering the required dose of ESAs using data from six randomized trials. The ESA dose was found to be significantly lower among those administered carnitine, with a beneficial response reported in four of the six studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/8\">",
"     8",
"    </a>",
"    ]. However, this meta-analysis did not include the largest randomized trial cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Side effects and concerns",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have not been any significant side effects reported with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    , although seizures have been reported in some patients. Concerns have been expressed about accumulation of potentially toxic breakdown products of oral L-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    in patients with reduced kidney function with long-term use [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Nevertheless, treatment with oral L-carnitine in doses of 0.5 to 2 grams daily and with treatment for up to three years has been well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/7,17\">",
"     7,17",
"    </a>",
"    ]. One study found no benefit of oral L-carnitine in children on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14200?source=see_link\">",
"     \"Carnitine metabolism in renal disease and dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since D-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    is not involved in fatty acid metabolism and the use of racemic DL-carnitine has been associated with neuromuscular dysfunction, these forms of carnitine should not be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations have been made to use intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    in carefully selected patients with renal failure and ESA-resistant anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], while others have suggested more routine supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/21\">",
"     21",
"    </a>",
"    ]. The Centers for Medicare and Medicaid Services (CMS) issued a national coverage determination for the administration of L-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    in dialysis patients with ESA-resistant anemia. Others have questioned the routine use of L-carnitine and raise concern about its substantial cost [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, the 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines for anemia in CKD stated that there was insufficient evidence to recommend L-carnitine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the CMS policy requires documentation of a low predialysis",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    level, the best predictor of whether or not a patient might respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    supplementation is unknown, although it is reasonably clear that a predialysis level is not a good predictor.",
"   </p>",
"   <p>",
"    At this time, there is no convincing evidence that IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    is effective as an adjuvant to ESA therapy in ESA hyporesponsive patients. Until there is evidence that treatment provides long-term clinical benefit, we do not recommend IV L-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    in this setting.",
"   </p>",
"   <p>",
"    A direct comparison of oral and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    in dialysis patients has not been reported. Supplementation with oral L-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    has been reported to have beneficial effects on anemia in dialysis patients in some studies but not others. However, most were performed prior to the availability of ESA therapy, and there are no controlled trials of its use in ESA-treated patients.",
"   </p>",
"   <p>",
"    The NKF",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    Nutrition Guidelines suggested an empiric trial of oral or IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    in selected patients for four months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/24\">",
"     24",
"    </a>",
"    ], while the NKF",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     Carnitine",
"    </a>",
"    Consensus Conference noted that limited experience with oral L-carnitine precluded a recommendation about its use [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/20\">",
"     20",
"    </a>",
"    ]. Since the bioavailability of oral carnitine is low and, as noted above, there is some concern about possible long-term effects of breakdown products formed in the GI tract, use of oral L-carnitine should be avoided until evidence of its efficacy and safety are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ASCORBIC ACID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascorbic acid levels have been variably reported to be low, normal, and even above normal in dialysis patients. Supplementation of 150 to 200 mg of vitamin C daily has been reported to normalize vitamin C levels in most hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin C, or ascorbic acid, increases the release of iron from ferritin and the reticuloendothelial system, enhances iron utilization during heme synthesis, and has antioxidant properties [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. These findings have led to its investigation for use in ESA-treated hemodialysis patients, particularly those with ESA-hyporesponsiveness, elevated serum ferritin levels, and functional iron deficiency.",
"   </p>",
"   <p>",
"    A significant number of observational and randomized controlled studies have been performed with variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/30-36\">",
"     30-36",
"    </a>",
"    ]. To better understand the role of vitamin C, a 2009 meta-analysis of randomized controlled studies found that vitamin C therapy, compared with standard care, significantly increased hemoglobin levels, decreased EPO dose, and improved transferrin saturation among hemodialysis patients with anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/37\">",
"     37",
"    </a>",
"    ]. These findings were limited by small study size and study heterogeneity; adverse events were also poorly reported. There remain no data to indicate ascorbic acid favorably influences patient outcomes.",
"   </p>",
"   <p>",
"    As previously mentioned, there have been several randomized, controlled trials with vitamin C in dialysis patients, with conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. Only one study was conducted specifically in patients with ESA-hyporesponsiveness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    functional iron deficiency. This report, which showed benefit with ascorbic acid, was conducted in 42 patients with EPO dose &ge;450 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per week, ferritin level &ge;500",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    TSAT level &le;50 percent, and hemoglobin levels &le;11.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    were randomly assigned to intravenous vitamin C (300 mg with dialysis) and standard therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/36\">",
"     36",
"    </a>",
"    ]. At six months, active therapy resulted in significantly higher hemoglobin levels (9.3 to 10.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    versus 9.3 to 9.6",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for the standard group), TSAT level (29 to 37 percent versus 29 to 29 percent), and lower EPO doses (477 to 429",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per week versus 474 to 447",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per week). Significant side effects were not observed, although oxalate and ascorbic acid levels were not measured.",
"   </p>",
"   <p>",
"    The long-term safety of IV ascorbic acid in hemodialysis patients remains undefined, with secondary oxalosis being the primary concern [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In the study previously cited [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/30\">",
"     30",
"    </a>",
"    ], oxalate levels increased only modestly after eight weeks of IV vitamin C, but information on longer courses of treatment is limited. In one study that was not designed to look at its effects on anemia, a progressive increase in plasma ascorbic acid levels was observed when 504 mg vitamin C was given into the arterial blood line throughout each hemodialysis treatment for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/40\">",
"     40",
"    </a>",
"    ]. A third study found that plasma oxalate levels progressively increased as the dose of IV vitamin C was increased from 250 to 500",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/41\">",
"     41",
"    </a>",
"    ]. After six months at a dose of 500 mg per week, 7 of 18 patients (40 percent) attained plasma oxalate levels that exceeded the range that would be associated with calcium oxalate supersaturation at usual calcium concentrations. Elevated plasma oxalate levels also occur in hemodialysis patients treated with oral vitamin C [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possibility that high dose vitamin C has harmful pro-oxidant effects, either directly or through mobilization of iron, is another concern [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines for anemia in CKD stated that there was insufficient evidence to recommend vitamin C as an adjuvant to ESA therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/23\">",
"     23",
"    </a>",
"    ]. The European Best Practices Guidelines suggested that correction of impaired vitamin C status can reduce hyporesponsiveness to ESA or functional iron deficiency, but did not recommend routine use [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/19\">",
"     19",
"    </a>",
"    ]. The guideline noted that use of high doses of vitamin C \"requires monitoring\", while the accompanying commentary noted that the risk of oxalate deposition \"precludes a recommendation for routine clinical use.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not clear at this time whether oral or IV vitamin C is effective and safe as an adjuvant to ESA therapy. Further well-controlled studies are needed before this form of therapy can be generally recommended, especially until the risks are more clearly defined and there is evidence that such treatment provides long term clinical benefit beyond simply reducing ESA doses and raising Hgb levels slightly. This view is consistent with the 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines for anemia in CKD, which stated that there was insufficient evidence to recommend vitamin C in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a short course of IV vitamin C at each hemodialysis treatment may be tried in selected patients with marked ESA hyporesponsiveness who are closely monitored for toxicity and efficacy of therapy. The use of IV vitamin C should be reserved for patients who are unable to achieve and maintain target Hgb levels despite adequate iron stores (ie, serum ferritin above 200",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    and transferrin saturation above 20 percent) and ESA doses (doses greater than 450 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per week). In addition, other treatable causes of ESA resistance, including infection and inflammatory processes, must be carefully excluded before starting such therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link&amp;anchor=H18#H18\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\", section on 'Hyporesponsiveness to ESAs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal dose and duration of therapy and predictors of response to ascorbic acid have not been determined. If given, therapy with vitamin C should be limited to a two to six month course of 300 mg of IV vitamin C at each hemodialysis treatment. IV vitamin C has not been evaluated in peritoneal dialysis or chronic kidney disease (CKD) patients. Oral vitamin C has not been shown to be of benefit as an adjunct to ESA therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ANDROGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the availability of ESAs, androgens (which may increase endogenous erythropoietin production, sensitivity of erythroid progenitors to the effects of erythropoietin, and red blood cell survival) were used regularly in the treatment of anemia in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. Their use as monotherapy for anemia in dialysis patients has declined markedly since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     epoetin alfa",
"    </a>",
"    was approved.",
"   </p>",
"   <p>",
"    A possible role for androgens in combination with ESA therapy in hemodialysis patients has been considered in a few studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effectiveness of nandrolone decanoate (100 mg as an intramuscular injection once weekly) in 15 hemodialysis patients in combination with intravenous (IV)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"       epoetin alfa",
"      </a>",
"      (at a dose of 2000 units at each dialysis session) was evaluated [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/47\">",
"       47",
"      </a>",
"      ]. Compared to the seven patients that did not receive nandrolone decanoate, the combination was associated with a greater increase in hematocrit (from 24 to 33 percent) and a greater overall response rate in eight patients, defined as having any increase in hematocrit (Hct) of 1 percent or more during a two-week period [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/47\">",
"       47",
"      </a>",
"      ]. The increase in Hct was also reported to be higher in the study group receiving nandrolone decanoate compared to historic controls receiving epoetin alone.",
"     </li>",
"     <li>",
"      In an open-label trial, 12 chronic hemodialysis patients were randomly assigned treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"       epoetin alfa",
"      </a>",
"      40",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      IV three times weekly with or without nandrolone decanoate (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IM weekly) for 16 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/48\">",
"       48",
"      </a>",
"      ]. The rate of rise of the Hct rate was not different between the two groups. Three of six patients in the epoetin only group reached the target Hct of 30 percent compared to only one of six in the nandrolone decanoate group, from which two patients withdrew because of side effects (acne).",
"     </li>",
"     <li>",
"      In a somewhat longer open-label study with low-dose ESA therapy, 19 chronic hemodialysis patients were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"       epoetin alfa",
"      </a>",
"      (1500 units IV at each HD treatment) either alone or with nandrolone decanoate (100 mg intramuscularly weekly) for 26 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/49\">",
"       49",
"      </a>",
"      ]. The mean increase in Hct and the final achieved Hct were greater in the nandrolone decanoate treated group (8.2 and 33.2 percent, respectively) than in the group treated with epoetin alone (3.5 percent and 28.3 percent, respectively). No serious side effects were reported.",
"     </li>",
"     <li>",
"      In another study, 32 hemodialysis patients were randomly assigned to receive low dose epoetin therapy (1000 units SC at each HD treatment) either alone or with nandrolone decanoate 50 mg intramuscularly twice weekly for six months [",
"      <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/50\">",
"       50",
"      </a>",
"      ]. The increase in Hgb in the nandrolone decanoate treated group (from 7.5 to 10.4",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      was not statistically different from the control group (7.3 to 10.0",
"      <span class=\"nowrap\">",
"       g/dL).",
"      </span>",
"      Side effects, including gynecomastia, hirsutism, menstrual irregularity, and increases in liver enzymes and triglyceride levels, were common.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these studies suffer from small size and relatively short follow up, and none attempted to achieve and maintain currently recommended hemoglobin (Hgb) levels. Despite the reported benefit of nandrolone decanoate with low dose ESA in two of these studies, both the",
"    <span class=\"nowrap\">",
"     NKF-K/DOQI",
"    </span>",
"    guidelines and the European Best Practices Guidelines concluded that the role for androgens is limited, with side effects precluding their use in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/2,19\">",
"     2,19",
"    </a>",
"    ]. In addition to the need for intramuscular injection, side effects of androgens include acne, virilization, priapism, peliosis hepatis, liver function test abnormalities, and risk of hepatocellular carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgens have no little or role as an adjuvant to ESA therapy. In circumstances in which the cost of ESAs is a major issue, use of low-dose ESA alone with appropriate iron supplementation would still probably be preferred to long-term androgen use given the side effects of androgens, even if this requires the acceptance of a less than optimal Hgb level. The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines for anemia in CKD stated that androgens should be not be used as an adjuvant to epoetin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PENTOXIFYLLINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     Pentoxifylline",
"    </a>",
"    , which has been used extensively in the treatment of peripheral vascular disease, may have anti-inflammatory properties [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. This may result in benefits in epoetin-resistant anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. As an example, pentoxifylline 400 mg was administered daily for four months in 16 patients with epoetin-resistant anemia (11 on hemodialysis, four on peritoneal dialysis, and one with a failing renal transplant) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/54\">",
"     54",
"    </a>",
"    ]. Among the 12 patients who completed the study, the mean Hgb level increased from 9.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    to 11.7",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Epoetin doses remained unchanged in all but one patient in whom the dose was reduced in response to a higher Hgb. One patient who was previously transfusion dependent was able to stop receiving monthly transfusions.",
"   </p>",
"   <p>",
"    This small, open-label, uncontrolled study suggests the need for a larger, controlled trial with this agent. Until then, routine use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    as an epoetin-adjuvant cannot be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     STATINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins, which are thought to have anti-inflammatory and antioxidant properties, have been evaluated as an adjuvant to epoetin therapy. In one retrospective study, the mean Hgb level rose from 10.6 to 12.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    over a mean of 4.7 months in hemodialysis patients after treatment with statins was started, with an associated 25 percent decrease in epoetin requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/55\">",
"     55",
"    </a>",
"    ]. About one-half of the treated patients were started on statins within one month of starting dialysis so other factors likely contributed to the change in Hgb. Small, short-term prospective studies have also been reported to show a small impact of statins on hemoglobin levels or apparent responsiveness to erythropoietin in hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the nature of these studies, further investigation of the effects of statins as an epoetin-adjuvant may be warranted. However, a recommendation for their use for this indication cannot be made at this time. Nevertheless, these agents are commonly administered to patients with CKD and dyslipidemia for secondary prevention of cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OTHER THERAPEUTIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficiency of vitamin B12 or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    is rare in dialysis patients but should be corrected if detected [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/58\">",
"     58",
"    </a>",
"    ]. The role of vitamin supplementation, as the administration of folic acid, or vitamins B6, B12, or E, as adjunctive therapy in the absence of deficiency is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?9/8/9353/abstract/59-63\">",
"     59-63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Iron deficiency, either absolute or functional, and inflammation are the most common causes of an inadequate response to erythropoiesis-stimulating agents (ESAs). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A number of non-iron pharmacologic adjuvants have been evaluated. Although the use of some of these agents in patients \"hyporesponsive\" to epoetin has been recommended based upon small case series and uncontrolled observations, the few controlled trials that have been conducted, for the most part, did not study such patients. Therefore, for most patients with ESA hyporesponsiveness, we suggest NOT administering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ), ascorbic acid&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), and statins (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) as non-iron pharmacologic adjuvants to epoetin. We also recommend NOT administering androgens as a non-iron pharmacologic adjuvant to ESAs (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See multiple sections above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/1\">",
"      SECTION IV. Failure to respond to treatment. Nephrol Dial Transplant 2004; 19:II32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/2\">",
"      IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001; 37:S182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/3\">",
"      Kalantar-Zadeh K, McAllister CJ, Lehn RS, et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003; 42:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/4\">",
"      Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/5\">",
"      Hothi DK, Geary DF, Fisher L, Chan CT. Short-term effects of nocturnal haemodialysis on carnitine metabolism. Nephrol Dial Transplant 2006; 21:2637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/6\">",
"      Kitamura Y, Satoh K, Satoh T, et al. Effect of L-carnitine on erythroid colony formation in mouse bone marrow cells. Nephrol Dial Transplant 2005; 20:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/7\">",
"      Golper TA, Goral S, Becker BN, Langman CB. L-carnitine treatment of anemia. Am J Kidney Dis 2003; 41:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/8\">",
"      Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 2002; 13:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/9\">",
"      Labonia WD. L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 1995; 26:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/10\">",
"      Caruso, U, Leone, L, Cravotto, E, Nava, D. Effects of L-carnitine on anemia in aged hemodialysis patients treated with recombinant human erythropoietin: a pilot study. Dial Transplant 1998; 27:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/11\">",
"      Kletzmayr J, Mayer G, Legenstein E, et al. Anemia and carnitine supplementation in hemodialyzed patients. Kidney Int Suppl 1999; 69:S93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/12\">",
"      Mercadal L, Coudert M, Vassault A, et al. L-carnitine treatment in incident hemodialysis patients: the multicenter, randomized, double-blinded, placebo-controlled CARNIDIAL trial. Clin J Am Soc Nephrol 2012; 7:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/13\">",
"      Vaux EC, Taylor DJ, Altmann P, et al. Effects of carnitine supplementation on muscle metabolism by the use of magnetic resonance spectroscopy and near-infrared spectroscopy in end-stage renal disease. Nephron Clin Pract 2004; 97:c41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/14\">",
"      Semeniuk J, Shalansky KF, Taylor N, et al. Evaluation of the effect of intravenous l-carnitine on quality of life in chronic hemodialysis patients. Clin Nephrol 2000; 54:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/15\">",
"      Evans A. Dialysis-related carnitine disorder and levocarnitine pharmacology. Am J Kidney Dis 2003; 41:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/16\">",
"      Bain MA, Faull R, Milne RW, Evans AM. Oral L-carnitine: metabolite formation and hemodialysis. Curr Drug Metab 2006; 7:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/17\">",
"      Trovato GM, Iannetti E, Murgo AM, et al. Body composition and long-term levo-carnitine supplementation. Clin Ter 1998; 149:209.",
"     </a>",
"    </li>",
"    <li>",
"     Verrina, E, Caruso, U, Calevo, MG, et al. Effect of carnitine supplementation on lipid profile and anemia in children on chronic dialysis. Pediatr Nephrol 2007 22:727.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/19\">",
"      SECTION III. Treatment of renal anaemia. Nephrol Dial Transplant 2004; 19:II16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/20\">",
"      Eknoyan G, Latos DL, Lindberg J, National Kidney Foundation Carnitine Consensus Conference. Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. Am J Kidney Dis 2003; 41:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/21\">",
"      Golper, TA, Ahmad, S. L-carnitine administration to hemodialysis patients: has its time come?. Semin Dial 1992; 5:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/22\">",
"      Steinman TI, Nissenson AR, Glassock RJ, et al. L-carnitine use in dialysis patients: is national coverage for supplementation justified? What were CMS regulators thinking--or were they? Nephrol News Issues 2003; 17:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/23\">",
"      K/DOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47(Suppl 3):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/24\">",
"      Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis 2000; 35:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/25\">",
"      Descombes E, Hanck AB, Fellay G. Water soluble vitamins in chronic hemodialysis patients and need for supplementation. Kidney Int 1993; 43:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/26\">",
"      Bridges KR, Hoffman KE. The effects of ascorbic acid on the intracellular metabolism of iron and ferritin. J Biol Chem 1986; 261:14273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/27\">",
"      Lipschitz DA, Bothwell TH, Seftel HC, et al. The role of ascorbic acid in the metabolism of storage iron. Br J Haematol 1971; 20:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/28\">",
"      GOLDBERG A. The enzymic formation of haem by the incorporation of iron into protoporphyrin; importance of ascorbic acid, ergothioneine and glutathione. Br J Haematol 1959; 5:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/29\">",
"      Deicher R, Ziai F, Habicht A, et al. Vitamin C plasma level and response to erythropoietin in patients on maintenance haemodialysis. Nephrol Dial Transplant 2004; 19:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/30\">",
"      Tarng DC, Wei YH, Huang TP, et al. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int 1999; 55:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/31\">",
"      Sirover WD, Siddiqui AA, Benz RL. Beneficial hematologic effects of daily oral ascorbic acid therapy in ESRD patients with anemia and abnormal iron homeostasis: a preliminary study. Ren Fail 2008; 30:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/32\">",
"      Keven K, Kutlay S, Nergizoglu G, Ert&uuml;rk S. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis 2003; 41:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/33\">",
"      Taji Y, Morimoto T, Okada K, et al. Effects of intravenous ascorbic acid on erythropoiesis and quality of life in unselected hemodialysis patients. J Nephrol 2004; 17:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/34\">",
"      Deira J, Diego J, Mart&iacute;nez R, et al. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia. J Nephrol 2003; 16:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/35\">",
"      Giancaspro V, Nuzziello M, Pallotta G, et al. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial. J Nephrol 2000; 13:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/36\">",
"      Attallah N, Osman-Malik Y, Frinak S, Besarab A. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 2006; 47:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/37\">",
"      Deved V, Poyah P, James MT, et al. Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. Am J Kidney Dis 2009; 54:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/38\">",
"      Balcke P, Schmidt P, Zazgornik J, et al. Ascorbic acid aggravates secondary hyperoxalemia in patients on chronic hemodialysis. Ann Intern Med 1984; 101:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/39\">",
"      Pru C, Eaton J, Kjellstrand C. Vitamin C intoxication and hyperoxalemia in chronic hemodialysis patients. Nephron 1985; 39:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/40\">",
"      Eiselt J, Racek J, Trefil L, Opatrn&yacute; K Jr. Effects of a vitamin E-modified dialysis membrane and vitamin C infusion on oxidative stress in hemodialysis patients. Artif Organs 2001; 25:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/41\">",
"      Canavese C, Petrarulo M, Massarenti P, et al. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients. Am J Kidney Dis 2005; 45:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/42\">",
"      Chen WT, Lin YF, Yu FC, et al. Effect of ascorbic acid administration in hemodialysis patients on in vitro oxidative stress parameters: influence of serum ferritin levels. Am J Kidney Dis 2003; 42:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/43\">",
"      Teruel JL, Marcen R, Navarro-Antolin J, et al. Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: a prospective study. J Am Soc Nephrol 1996; 7:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/44\">",
"      Gasc&oacute;n A, Belvis JJ, Berisa F, et al. Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis. Geriatr Nephrol Urol 1999; 9:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/45\">",
"      Navarro JF, Mora-Fern&aacute;ndez C, Rivero A, et al. Androgens for the treatment of anemia in peritoneal dialysis patients. Adv Perit Dial 1998; 14:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/46\">",
"      Navarro JF, Mora C, Mac&iacute;a M, Garc&iacute;a J. Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney Int 2002; 61:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/47\">",
"      Ballal SH, Domoto DT, Polack DC, et al. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 1991; 17:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/48\">",
"      Berns JS, Rudnick MR, Cohen RM. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 1992; 37:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/49\">",
"      Gaughan WJ, Liss KA, Dunn SR, et al. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Am J Kidney Dis 1997; 30:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/50\">",
"      Sheashaa, H, Abdel-Razek, W, El-Husseini, A, et al. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis. Nephron Clin Pract 2005; 99c:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/51\">",
"      Benbernou N, Esnault S, Potron G, Guenounou M. Regulatory effects of pentoxifylline on T-helper cell-derived cytokine production in human blood cells. J Cardiovasc Pharmacol 1995; 25 Suppl 2:S75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/52\">",
"      Bienvenu J, Doche C, Gutowski MC, et al. Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J Cardiovasc Pharmacol 1995; 25 Suppl 2:S80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/53\">",
"      Navarro JF, Mora C, Garc&iacute;a J, et al. Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. Scand J Urol Nephrol 1999; 33:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/54\">",
"      Cooper A, Mikhail A, Lethbridge MW, et al. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol 2004; 15:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/55\">",
"      Sirken G, Kung SC, Raja R. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J 2003; 49:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/56\">",
"      Tsouchnikas I, Dounousi E, Papakonstantinou S, et al. Beneficial effect of atorvastatin on erythropoietin responsiveness in maintenance haemodialysis patients. Nephrology (Carlton) 2009; 14:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/57\">",
"      Chiang CK, Yang SY, Peng YS, et al. Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammation effects. Am J Nephrol 2009; 29:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/58\">",
"      Hutchinson FN, Jones WJ. A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease. Am J Kidney Dis 1997; 29:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/59\">",
"      Pronai W, Riegler-Keil M, Silberbauer K, Stockenhuber F. Folic acid supplementation improves erythropoietin response. Nephron 1995; 71:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/60\">",
"      Ono K, Hisasue Y. Is folate supplementation necessary in hemodialysis patients on erythropoietin therapy. Clin Nephrol 1992; 38:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/61\">",
"      Bostom AG, Shemin D, Lapane KL, et al. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/62\">",
"      Cristol JP, Bosc JY, Badiou S, et al. Erythropoietin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation. Nephrol Dial Transplant 1997; 12:2312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/8/9353/abstract/63\">",
"      N&eacute;meth I, T&uacute;ri S, Haszon I, Bereczki C. Vitamin E alleviates the oxidative stress of erythropoietin in uremic children on hemodialysis. Pediatr Nephrol 2000; 14:13.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1936 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-42AE1A7C96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_8_9353=[""].join("\n");
var outline_f9_8_9353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      L-CARNITINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Side effects and concerns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ASCORBIC ACID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ANDROGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PENTOXIFYLLINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      STATINS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OTHER THERAPEUTIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14200?source=related_link\">",
"      Carnitine metabolism in renal disease and dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28005?source=related_link\">",
"      Diagnosis of iron deficiency in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=related_link\">",
"      Inflammation in renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=related_link\">",
"      Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38521?source=related_link\">",
"      Use of iron preparations in hemodialysis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_8_9354="Lactating breast abscess with skin compromise";
var content_f9_8_9354=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68502%7EPC%2F60139%7EPC%2F79340%7EPC%2F59342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68502%7EPC%2F60139%7EPC%2F79340%7EPC%2F59342&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lactating breast abscess with skin compromise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 349px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFdAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDa2/Lx1p8Sb+R09RXm3hTxJrPjbVGNrD9i0WBv30ufmf8A2R716lEUUpGg4Xge1PE4vlVo7s8rDYFzleeyGFdmB1+g6UiI0jYUZOcBe7GrDkZY5Ax1HHNdd4U0VY0XUL5FDHmJCOg9TXmU6bqS1PXlKNKImgaKLKIXF0i/aG6KeCoqzdOzvtQFmPpx+talzI05KocAdWzkCua13WItODW9mBLeMM4zwvu3t7V6CSgvI86UnVloQ6ze2+lQb533zt9xVGST6D/GuA1m4u7pjJfOixHlYVOPzrRmR5JmluZHlnflmPQew9qxruP7TIY4lPHVyeTXHWxDekTto4dR1kc5qCtfzIjDyrNCTtBzvIqMW+5wFUDHTPpW9Lp7sVCrnbjr2qCS084hVRQ2Tlgetc1ztikjn7qy8xisIyx647UyDSQUzMw3dDx0+ldhb2IhT5kG786QhBuUx5UjIHr7UmyrGBb2EMBBUZI4x6/Wr9va8ElBsHfvV2O3IG4qcnse1TQQ5JPQnqP6Vm2XFMrWtquCegJwe2KvxxxRbDEGZsZ3DnNSRWimTnK9CoHNWbe3lVH2syqv3QVBwPbvUtWNooqISUG4Ehc55/SnKmSVhVQSM8dSa1LaCNkAwQeoLDmp4oFVi/lqpJABPUGkjS5mRaa5R2k3My9CxzxV2zsYw4favI57YrQRY4wVDncTk+9QoYo5WIyZGGSpzj8qt23JbJRCi8BsBeeO9V7i78vaka8e/Tmq888rFIgGVW/ujAHvmhA8hC8EDne3Sk5DS6lW8kmkmKoSFIHQ4zUlvYptwAS7c4PWra28zMhjAkLN8wfoB61pxWuwRuSpxnB2549KSi2NyRQtrARJkElVXlTyTWraxZUEoqg9s1YjTBVQFUep71KsRyFJCkjofStErGbbYixMwxsyB26VbijAT5uv8qI14QMR7beDUm3dgYP8qaQCoi5BVRknnirJUcY78daZGNoYk7geg9KsDaCOCW7e1aRFchKZbkEADk1PDGMcYXjGacQdoXZkmnRqrKGI5qle5LY7YMHjkdOOtOMe4qMdt2TUqqcjj1p4TgBx16EdqonYiKbVOACO4qv5YC4464q4zAcY69eabIucemMUMaZQdNu3aOT7UwLwuAMZINWnTOAoA465pr/Lnjng49allp2KZhyAT27U9VG4jOARjmpmGTgjnpVa2glQTmSZ5N8hZQQPkH90Y7cfrUpal30EPDFSO2aZjGO49TUzMchiPmUYOe4pmVbchyccj3pj6AxAcjv1/Cq5VuSAOTz69KmI+fnoRjFDAgcDP160IykiuOWc9MjB/wD1VDny3UBgMc5z3p8mVkHXIJ5xyR1pkmTIXIHByAOaaMJK5Occ4I+bnJqpdAACTrjptHWrIUKhwVycY5qOQ5mALEKOCD3rVbGRAYVkDrtG30FRfZ1YASbdyjb9ferKINyk8epHRqlMGTnoO2Ka8iWjiNA0a10XSoLGxiEcES8DufUn3rSiAK52gE98VMEG35gDng1p6Dpb382Sv7hDliP4qyjF1ZESapxJvD2jrcEXV2MQJgrx98/4V1Mimb7zFI/QcEj+gqNrmIFo4PLKwj53PEcQHqe5rjta12TVi9tYO8en9JJ+Q059B6LXfaNGOp5zcq8rIsa74idnNpo5BVSVkuR91fUL6n3rn/JWLdjkk5LE/MT6mp441ijVY1CqPugcYoKkZwck9q4alR1H5HoUqMae25S2O4bjA6Ypi26xKwXjPXnrVmSOVI22qCxyVH9DVdI90SPMB5nopztrJo3tcqzs5X5ArYySDxj/ABqCZhCikRFnfgbe1X47cRriMEDJ+buaSSESL/dAIOf4hU3saJGfKreWVIIJ4x3pggEe0MWY44H86utCV2kElfbjNTRxFwEJ6ck5qZMpLUpxWpzkKcdfm9MVfhRISJHIwq5AxnH09aVT5keY3BXOMjnp1qQEhfl6DPAGcGs+Y2jEY5DBXCyFjznHT6061aQkbtpHUMeOfSks/MO9gymMkgKOCKndYkO5uGJ65zSWrL2VhsalXkUYG48D0NTTSRQhlabDYGAxxihtuSGZgSOxx+NV5QWUfIpYdGYcgfWn6D9RZruOOEuSOPmJx+VVxvulTe2AWAyAQCKm09JZiWdNkecAu2T9cdq0YrUoobYZBzxnr6GhK5Ll2KNpbSPCNnmJ82C0vXg1ftrSIR8Ju/vE/wCeatpHtVVkOW7471Om2MjcCR6Y4FWlYQyOBQ2eg/vetWI4GLA5O3ripBnPDg+4PFSbdijcTxzxTAYELFgxAz6VKiAAbBu7Z70xW3cICFPU5/OpAFCkKMY96a8wYu0jJIAB9adEobAwenTGM0pXoOdoGQO9Mlj83chY4cENg4P4GqEWUXgbeBjoO1Sl/mUbCF/nWP4f8O2uhvPJZyTs8xy3myl/yFboQkDbyO/FWn3JdhVDNgMDk9cHj6VbRflAGMj2pixDhc9PTip1TCkDuatIhsETHAXoafgFVDAg9qROoyPx7VKMbm5yOtWlcluxDJGMnIzx27VDjLdxxk1Ycf7Rxnt3qHkKARg+3epY0yCQdWA56EetRMMScjjjAq0DubHTcKicdS3fpUWNUyuy5yORkdqXCq2AN2R19ar2bXe64N2qqFciMrnle2asMihBydpII9qm9yvIr3EZycHjHPrUKr94KR13Z6fhVyZSSy4BIG2qF3CZE2q2GPcGqfcpPuPcgygkEjHr0prYx8ytjg/Wl2/dDLjI9aG+VGJOOfyoM2VlXe27k4JGKdIrIDgYI/GgE+Z1PoasMhYb88j16U0ZSZTGd6rj5R0x606SLKEqCV/iFWBEPlFPRBwDgFhg1pEza1K/ljaoLjKgZpdrf3d3vmp2iOMKAWByR/OmY2FgQOuRmqsQYul2Au/MlmkWGzi5lmP8h71oLqK3trIbZl0/QbcZluG4Lge/vUnirUdA8M+EYYdWcpZt8qIoy8hHXH1rh47i68S+RcahbfYdHhO6z00fxekkvqfbtW8eWjG55tTmry5VsaV7fSa8ixxxNaaFG37qA8PcEfxv7egqcAbcAAL0AoTrzwPSpCyDjgECuSc3N3Z2UqcaashhQnr/APrqOVkRQvJf0A5ppuFOVU8gcL0zTWEspJIC44+tZNm8UI24gbvl9BUDfKQArb896tIpI4+93PbFV5y6uxBJU+/Q1LNERk7WYffXOetEpAj5Ucn6VHkyMrKGKk/M3enSRAuCVJOcjvWbl2LSvuNbzOqkYXtToYzPIygfuyMEgc1ZSIKuXBP15qVV8r5U6t2A6VHU0iitHAkcZSMbUB4x61JGUjjaWQsI84BYYzUkLRs7KpKkcDIqRV3p86jOCSM5pF6og8s7FKR43EnpzUN/HdSW7R2LxQyv0kYbgnvjvVry5JIk2PgA/Nnnj0qcwliqpGAmc4Pai1xXsYelaULNS80st3cnJM8jZP0A7Cte3tywDMfc5P8AKraosQwFAz0pJmLFB5vlbjgAYya05SOZCxxKqFASADyalV9m3aRkcZPpTQETjeXc9jQFlZzsQbfWmK5I8iK4xuOR1HSnxSgEsOWzTBFKOXXjB+7SxxTL0baPpRYOZllHLfKMEdfu5xTxHlQwBA7npVVVkUNmTaWxj3qwolKgt1HU9qqzFz2HBB5plDMzEYAJ+Vfwqb+H72QRUSqFYsWG7v6GpgACRtO2qUWg511HrkL3J6c1IoyAM7QD+tNRAeFqXyQBk4Y+nWq5WJyJY1RTy2R054q2pwnJ4PcVUXIxkAY9KsB0OOWx71ookuZMmQd3fr0zip1DMFziqsbfOPmPHbrVgOpcKu1mbpzimlYTbZKOOOuPbinFF/iGT6U1RtJV859M0/IK7eh7Zp6CuRhl3AjkdzUcrL5gUdO1TbVAAPXHX1qBl4J7ipZcWMJXeWdsAAt7Cj5ZEDghlIyCKTbu5IJB65PShEAX5RgAcelS0XoNkQH7vP8ASomj3r7EY/Gp0bK59DigqD/u980txXaK6rlMycHIzx3pjRjLMeB157VOVCuQGxu/n606QbWGR2Ix9RVA22ZrIuzIAO3oahY7jgngjGMd60NoRiDyAwP59qplcOWJHB6dgaRSZXIWNXeTiNQcnpirUCqWTafmK8EjtTUjAds8BuPxp6gKQdvK8DI/WqS0Mp7jmU7geOo6dBR5QPzDhuuFqQD5skHJ4PpTohtIXjr2FWkTciXCsMA5zyc9qgaPPVeno1XZYyw4OMcgjrTljVBggD0yKohnm+t2a+IPFB1XUV3W1oPKsrduQoH8ZHqTWmFAGWI57ilRU4Azn1p+AAGbkelYym3qzKnBRVkRnqQnT1qKT978gILDt6CrOwjJAAB/Oo/Jx83yk4+93rNtmqikRqFJ2qo4HOTS79y7hhecZz1oIQPsU84yWx/WnNlVwPuDn6mobNLWK65UOvUE/eFQ4ZjsT5ec56VYLNj5iUHrn+lSRxFwGXIUDp0/OobuWkUBG7MSVyQOParUUDIcyDGedoNS7kiXnAyecAkmp5bZWlj+QFl53Yzj+lSWkU3dfMSNhkM2AcgYPof/AK1TiBmKxsdqLk49farTW0TMrFC7LypOMj6Cnbeny4J6Z6ipsWiuY4wzYADj07U1Ynzv3gKRyAOp9afcecFK2oQSH+J+g96WNfKhSN5XlYDOW6k/hVxiRKdhsWAu0biRzSu7cbVGfegL5mAyng1OkTDAVcH8yKuxndsrYmJyxHr7U+KEyFjg57nOMitD7K+3hQx9DwBU8VuFHzFFPfFNIaRUjtzsxgAHt1qcW5QZZl56Z6/pVhnypAZRjqSKiYRgYHU+9PlHsIWRFI6/hQwZhgjAqITKJ9oG4H0HQ/WpzICwxtx70WsKzY5YmGMEMfXp+lTJEpAySfbtTFEZOXfb6c1IFGPvAg1oiuVCeVEGyqbc+lSYCqB1A96YyYGN23n+9mmiMMcEt9c1QcqRMpHHP5igSqM7jj0Bpu0KMAAjuRk0hIQ8KD2wetUkS02SiYDG0N17U83Ct8gX5/cYqNCnZQG9SKUMMEleT700yXTe5PE4HQYz2qbcrkBgoYdyOlVC/wAisWwenWljlC8jrnB5p2uZvRmjHNg9MkdSacJk34YAEnvVQPzweD6dRU8Tqdu45+tJq7Gn3LYbcD3GOAPSoCCWwBx3HSlLgKCM9e3ao3feBhiSTnFJoa0JT91t2MkjNNLNj0NR5PU5BA5zUW4blORg8Ee1Qy0yUKDyOvcU9VyTuB68jrmoxzk5HFPRtuAD2/KhDvcQKrMHKnK8fnSSK2CrYOOhFTlAFYr9aa6gHnkjv6inYdyrMCVwcbsCqsluAVfYSW+VvT1/Kr5jUksDtOOOKgmUn7/K56AcYoC5DGuEIzlgeAaWQbjn69qUExxkKuUTru64pZo8fMuSWXoatIyloyEbsE8nHWrSKnHPTHNQwJIFKy4HHarJRtgOAT0JqrAwVMY4GRQ+QRk546mnRZPbtwKU9f4h9KpGbRwqEdhk55NSEFgPlJHT0pBwQVwSPSmrK0jBRjPQ+tcg7DioOOSo6mkDKzgBgcfw0p/1h/iHuKUMu35Sv1HH60i0VbhpY5MQxq+f4QcfmaNssijzNit1xmrqp8vHJFVI4bmW5dZREbQdBzuNRsUrBaQK4zjec8tngmrjRMY9owCfTtUsKlOBsUdh7VKgIOT1qfIvYqR2xWTCEbAOc9atJGqkgc+wqVkUkPuJAHTtS5VELycKemOpNQWiJ0WMnZt3D2qA8Kec+vtUrnzcBU/OmtFtcfIxYj8q0jHqyJS6IrkE/KvU96lht2Y5LDJ/E1Yig2/M/JP6VPGBGByMnk5qrpEKNyOK2Vcf1qdFCrgHGeOe1RtOUBkIVFxx5hxmqtxqkdvG7SHcQM/KOv41PMjVRNFAAuR0Pr1qOWZA3IwfVhWDH4ht43kkuFaO32/eTlvy60k+r6RcReYfNmJIIjcbannTK5WuhsS3HlDlYsMOrHmqVxe7ExjDDsR0rAur22jk86R/3fUIOSB7en40W+vRJ8wtXVJBld4Dfmego531BRvsbNveGR/LMcy7ujbMinrMPMZU3ZxkZGOai0/UQsQdTF8wLAlqmSaO4BLfM/J+Qccepq07rUaVnY0bSBpokeVDH0yGbcc1YEKpksSSeMmo7bBiLeYAMcjNSPJGqKu4vz0XnNaJhytiERhOGHruC1GbsYKq3ydD2prSBiTkDH93tVV3OwvGXODnpiq5u5tChcutd4Qbd2OmcZpsl6sT/Pnn1ODWZHd53A5yOg61BPhx8x+nfFLm10N1hl1NdrmNnxlg/pmnpON2HfAPTj9KyI0O3bIx9iaR2ZWJ+YrjjjFUp3Jlh0tjb83B+XD/AEqzGsMvPAY9Qa56K4baFWQbW7A5NWVuB8oBOfXNUpGM8K2ba7o9w6Adwcg1IrurYIHsc9aw4rqSM4cZ4znp+FX7e9ygy464BP8AhVJnPKg0asLhgAG68GnAEc4P+e1VIpcHJ7/kanWTnOQMds8U0YTptakgcHhs9xnHNMkRSThgc4x7VJuDA+voajKkEhgCO3HNSxIIx8zKTyOoH86sIG8sDG0etQwRnIJHPXFWYwAeM7c9T2qS79R8POcHOecHtSSrkDYdpXlc9vanqgVsgjHP4Uwvg5xlfYc0w3ICDjdkYb09aiKHAbo2c/pirSpl2GQR1XtxTXUbeRjK4IpjbIWjIjILfN7/AF9KjkUZO1jg4OPSptoIzjleMnrSkgR88npgU0KS0EUDCsCFx1qUABQQefrgUxQC3HI7UpGGKnHI+7mqJEjHzY/iPPHpTCGBIV+KITJj5gQ4OCRT3DA420xWOGQDJOc+w4qSMJkbM5PrwaEwy4HynPWpPLG7Jz7YrmcSLilCMn7x6mgxho9pXaD6cVIMbhuz7GpIsPlTj6VLRSYyJUQbFTil8nzGOQRzwc81NtUgAH5BTiARlTjnrjmpZcSFokZgzICy4wWHNPSNi6ljgZ/zmpwMoXY4HQAjmq9xKFJReZB1OeB9alrXQu6W46UpGMs5PooHWoz5kvbaPSiKLc2+Unn8zVpyOmdoxnA5NNRSDWW5UMRTHlgBu9SxBlfaQx4yz5pSAoyAx3etNkl2wSMzrHCg65pN9hqJI00aBgWIABP0rnr/AFSNJ1WFpFO0s0oQkL7Z6Zqnf6iUlKlx5aNvJI6j+tcnqXiqXULoLY/NGAQSegHtWTlc1jA6KXxAkCxytFKXY7Wac/ePQGsZNWuby+kk8pScH+LC7R6AVnyw311KJbmdHkC/d5IWte0VI7cbpssvGAMCjlvubKFiOGeW5uZJHiY7lAw44XHsKp3Vnd3EmYhLGjcEoCB+HPFbd1KY7NmhDkoM7VX5n96hSSZLaGTEq7jnDn9KppIfs2zGj0SckSXbTMrDPlrzu9z61oW6zsAsu4wxLxGBgKBWpY3MjNI2eQDjjAx3GalnUSRLEiBoicuQeMntmjlXQXI1uZ76si6gfMgt1jVVCxRruH51qHUZJIlfHkRZz6DHviuU1yGG3mCbMOpxw24EZ6cVPDfTuxM00kqBR8oXCr9fejbRlqN7NHoFhdxnB3Kyk8AHrWg0qni3QMTyQOPwzXL6Y0QtYpkQM7vhuTkL9K2LdlD7lU5P3c8VqloaRp3ZckuAF5AGey9ajmxs2qMAjOSaZMS+D94jv1qMhfMQyYJPvVM6YwVtDPkaRGDR8sTj5lwBSxPKswDB39MdPrVqeFGYBF3Aj14zUBtz5qKhG1eGUZ5+tI2XL1JnZ2O+QAjBHpTPOXAL4VSdqjqP/wBdVpE5O7JAPYcDmnyoM90zzjOP/wBdCfYmy2Jwu1mKlUYcjB60KxI/eHDHjrWe4icGJn2Htzzz3BFWbfzBFtMjSFeAWAyKu/Yhq25Os5JwxO4dMVat5RncG2sOobuazlTeuHyCDyT3/CjIJ3gEfqKakLkUtDoob0EiNkII9RV+NwSCwBLYxz0rmknwwAG4dDz0rQsrnIIZiTx3rSMjlq4ddDejlCsNxzn07VZxuJbHyjoQOKy0lAVc7d2ev9KuWsrHKkkH9KqyZ5k6Tiyyg2nJ4HcZqeP5hkY9cnuKamHXPDAdqmhwQCMFcdKkz2BQAuOR0qM7uWHc1PgbMAYzUbBSDyfTrTtYaZCZGUOSBjsajYo3HJJ5PNPYtsy+FbofamABl6FSOSRzzSLQRoQmIyemOtPBC/JJj1+hpygHvkdx1psy4AVRk44I9PSmgerI5QQ4KnP90DtU0ablXdw+OaiTdlldcr27UqOUOWJ461RMkS45MmCDnnmoZH+Y4JGecZqV2HlhjgAcgimRSYX+EgnIzTuSjiwMDg4qaIHJD556e9NjTJGAKsohAOGGfesbGQxlUckLnoPrSnOFwVC9WGOaVmCP97PtjpTkAUE+tZ2NEDuI1yR8o7CgOZMFo2A4x7VHMWCkrk+tRNKVAx1Pf0qTRbXZJNOc7EyG745xTYIyMHoM8ZP61DbgOcse+c96vIVPB6UrpAk3uAiG/wA0sRgYAzx9aVnxnPHv3NSBlXk4x0HFU7+XJBwFiHJOaTdkW+xDPLJKnykxt09h/ia5nXpYreBW1C8ISNeEB4z9K0r25QW8kk04WMfdRerE/rXluq3kus6u0LOzRodoK4AUHisZbmkFcku9Qm1e4kjQBIV+VRn270yytLeEyxRN5QAy5AJLn0p0GmC3CxxlnUnir1tbTIcKxCtyyE4B+uPrVwSR1RtuT2MbmNmmZoxwFDHPWtExqoDZPHQN/OoYE/eqIR5sn8R6gY7CpblblJQ00Mo3cpkda1UL7Fp32LMl4ttCgkYKzjhf7wqy1u9wsZWRievzHgfSsmzlgubwRkqXjPzITkit22mdZdpALgkJjgH/AOvUuPcHpoU7aUqzRywsFXGN3171O93M0gihiAJGAcZ4+lVbxjHNunLAP0VeKFldkBEOAeCcYpbaBylS/s0mLLNJh8dQOfwqCyxJcpHCCkSd3646ZxTNVnd1dBtUMMc/1qXRYgJ9hBVjxz2A9qiTWxcYHf2CwKqxqQSeMkU65hWTncCnpGcj86pRW/lwjPQjnc3IFTRTFIwBknJwg7+1aX0sb04a3RNGqoMZbaemD+lPQbwBjaP7vem+byfKXkdveokVkdt8o3kctn9Knm7G1iyVRZCA4BHJGetUpXVG4b5jyOeM+lPdkWPLD5vu4HSqGoSGIqQMqOXIFUtTNK+jZM0hWBk2546KP85qu3mlYo02lSmW3EnHoPpTYoZmCykrszkY6496cvnDPloxjGc8d/atFHuQ3Z6GdctIgZosq7HAwcqTT2uzbC3kdkcPnOB/jV5LA3ZMs7yRu3ylFxwag1K3t1eBDE3yjbnICjnvWijdXY3Xg2ok1rN5rlo2JD5PParUaL8oO5B1GDkCsNoGjLtCDGw42g9fcVp200nkqM4k4BB7U3BPYlpx1TNVok8tWK5IGcCkBCAGNRsIziorN/lGRkg1Mm/IGAD1HuKys0Um3oy3HcL8u45GODV+3l+YEn8elYSyZLMvU9V71ZimHy5LZ9e1aJmVWkmjpIrnJQggA8HHatW3YyLnvXOWjliNwwfX1rTtJ8S8k4OOD3rQ8urTtsaqgksPTpTJY8qSoG7OR9adGwOQ3I65pX4DY+vFO10c12mVnQNtMhIVxjaT0NKMK5B2g46AUPG7y7mXOCdrDt6ZFRtKDMBhcA7SfU1GxoifYQ4K4z3qFRub5SeCR9DVg8gDGahOQwAPI7VTBMZIWILN06NgUwqDg4G0HI/+vTnGQ3GCOooXBxjkY5oAjc/uSBgoeeKhDbRjaGHY4qdyAeCMAbSKiCqowTu9DVrYzZzXGBtIUD09KkXGMlif61XU/Nx0FSeYFIJz7isJaEpMndgCCcbvQGmNIoGD+Z6VG8oxnp3Gao3MzbWEeMfSsm9TRIsGbcxK4/A0iYSNmPLscDn7tVoic/KAMjJx0FTIeOwI6fnUt9h7k8YKj5Vwc4GasoyKyhyc9gKpWzgtj5uOSfSrDS7JC/8ACeBUto0ih8jBXfDEyn14wPSuc1bVxFcNDHJuuUTiM84z3rRW4nllZY0KgtgMTnisHXQsEEjQ/wCt6SPis5PQtLWzOc1d7i0spPPnVbkrkiIfy9O1Znh+xRonmHJzyc/MeP0rLuYrqXVlgTM7bjuLZ2dMkYrr9KgMFs0TpmXjaOnP+NENzpirIhityoLhiSoxzVVZHWMBCGmfj0A5q3cqUDKw4OT69KxmvALmFhuBI2/KO2fSrgrs0UbnWaZA0KRrsKFssSDzn1PpV+7uN21JEVyFPKggrz74rm7bV4Uud8BlSPcdoLjeV7ZP6Gr0+qRxWzSalO8xnJO5SzFe+M9uo5r1KMFy6mkrJHN+LpH0uKPUkKpJBMDuIAaVSQGVsdQO1dTJICtu6MQJSHGSfT/9VefeLLxdTe20m2ZpRNKryPn7qAgn+grt4olmhQ7m2qoCnv8A/WrnrwS2IWtrmjIrMN8pAGeATk1Tlu8/ulG0dwByeaksTETIZJCQzEuT37YHsKpz3C7lMY+UnuOvvXJPbQpLUbK5aYRuAyL1UKKu6RYiIjbtAxk7iST3/OqVvIo/1g2u/St+ygE0H7piiEAsVP3qyWp0QiaNuRMxCOAG6++KvqpeR02ZI6sBgAVirGWjdMfICMrjg/WtaESySxosojQffAx81Fja3LsR73imVVyW9uw9amVVKYPXoOfvVYuVjJ/dYXPPqTUCqGIU8g9T3FaRXciVTS6I5V3SLhMBRkZPf1qlcXDQBeHxnDDPXPpVqRwpMcbAjrWRewzTqwDsqbSBjrk1so67mLqWZKL2OMuzlUXdwFGav/2hAAoZ1UOMg9zWRYaYgTD5ldRtOeRWk+mwXkKxqdjIOCeNorpjB2OStXjswmSNyPs8rfMQTzzmszUYrtZvkdpYs/McdD/+qtW104RjarFyDnI4qZTGuFbCEdcnvSlBoyjXSempUjZMoJovkxwc9BTUVlRngYkE/LkfeH1/KrqW8WXKsdrHgdj9Kv29rA0HlOMYGKuEXszWWJUbWMqG4KcmPZtODz2xViO6Z3AHynHTPWo5oRDO6OqlVwOuM0lqmCrZAXHRuSvNTKKOiMlJXRdb5iskQ5I5FHBI3AgDsBSwRnk7iMetMZtrbWBBHpWGqZ0W5lY0bGb59pJOOAe9aKSMuOeOma53eUl+U5BOfQita1l8xUYnJ6kVqmcdalbU37eXBBf5vf1rRhIZeQAOhFYVlKrfdzjI7Vr20jMMMKqL1PMrRHTF9pHCgfzqptRcHOGPQjnJrQZM+pDfpVJYvtEJEo2srHbjtjpRKOpnGWhOrMyfMBn1HemyDg5HB7in4IYjAyOeaSVc4559Pai1xkbEcZ5Q8cHrUBxsYHnn8TUu0kso4A/nSMQ3BXPBGemcUILFWf5nxngen9aidl3kA9P0qWRT5x9cd/61VnKLJ90knk4FUhPzOfYhcDOaZvwP6moJJP8Aa6dMdqQt8ua5ZMIqxJLISx5JNUzgkl2yewqKV2DHBA54qNnb5BHwM9e9ZN3NNkWkJViSCW689PpRcSt8gjAZnPJJ6UOgIxn7vUA9aQqrSIAhG0ZJqV2Av2z+WoJAPOPrSyyFi7FlAGT9arb0WEDDZB4H4VmXdyk1yFeUII8A8Yok9bMuOxKbpklaKMHcRu3NwMmsHWNTgh0q4N3ebpnJwEHPXjFT63fwozSqzplCu7d0OOK4+3tZJ5jcPIDGhy5fjA7n9ayd27GsVfUg0OWUXoIWQckBieeeua7JWjMZkDLkE4x2/OuV0OFRqEzLOZYv4dnAIz1rpGMaPsUK2F4VRjPpmtYKyN7djG1KK7e4iuY58x8goT1H0rH1CNnhzAcSpl1PTP8AhXYvbF4cNtbLbSFH+eKpXOkxS5fYyPjacjg1UVY0Ujz+5vtQidTc2V2pIChlQnj2IpUvNVntWeGK4W3X7zzqVQe4z1Ndddm9sEGwvIowMKcH3xVz5rizZcKyEArI/J6dB712Qq8qsipNtXaKPhHRoI7JryZ2e/c4LOMFhnsPStye6hG63hkxIeGx29cVl2dqyTKrt5aBeTnk1pWsUTLJKI3Hr2/GsJTciJLW5XhT7JaEysWZudp9KjFyXvo2Zdp4UADt71Bd3jicRwxl9vy8f0p94/2h84woXBBHP0B9a5m1e5vBM2YYonlTzEXzXb7mei1uWyJbwSP8wJIwu7rx0Fc/o1hMzxXMweJ34XPB4rcVDLmMlWKnB7ceuKd0dUVZbly1uBIgjUHAODnv61POcfOYyzY4Vep9qpx27wyGQklWGFB4wKuqeMnbuI25zVRV3qOTXQbuLAbcAsed3t2z9aSYyRuCkefMx06jnmnAI8oREyQdwHQKPU+9EVzE4Yo5OwkF8fMSOwq3qZydivORBEZJFPuMc49adpsi3LkAMDt3YY4wPaq1wtxKvmBfm35VQpOR05JrRsYf3mGCrJtGW6j6V0U0ranJXlZWRNMWjjdo41CAEFdvWqCS70UuNuOcc5zWuFdAfMBPpjoaq3NykeI541MmOwzn6e9dUY6aM4eaLdmPtriKTfscgDngYzWZfmYyM1uoZQflLN1rZitYyhMZXdIPmXsPYVC2mhvm+ZVJ6A5p+zk1oc6nGEmZSXMoKgrsbOOOgNWIZ5uTI2TnINRXFu0Mu3aMBjjnqPWpHg2urxOAG5K/0pJu9mV5xH6pewqA0mFTblix/nSWM8N5a+ZayqYz90k/nmlms4rnY8qBsdVYdaSK0itJWiiwuW3bBwMUpqLXmdNKTT5ehfG+NNzA4xg5702SRmdmIAXGdxqZBuzjAVQOM5pSiuhQqoB9TXG1Y9KL0KjLgK3OVBOfWrUZGQy8Z4OPWo5FMSbUHpwT1p0QV1GOD6elEWOoro1tOlbI3Hr/ADrXs5SVU9QevqOa5+2kO5e7CtezcrJ8g6n0rVHl146m7bsSDkc5oYAqygYb/PNNtzjj1FSsuTkYrZK6PNekiLk4Gaa4DHBPOPzqTbjkE80gGc47/wA6mxaZBIHR+D8hx35qOQpkBiWZewHWp2GXG48/SoXXcdy4LL2A7VNi0VXAZ8jIPT/61QSLlzhfzq26FSSrBVPSqQlAyD8xz/EtCEcK8uCfzxnk/Sq8t0UG4ZIFZF3fhFJyNvSodL330pkY/ugcgdzXDI0ir7m7a5lBdjknjAzUshLOVGABgYp0EeMZPbqPWoC589gQQA1Zxd2VLQmtmCSorjAPPsKnLky5DHLkjbj0qnkMyShuRwFxmrm/YA3PuQMYqkFyEzfZSZ5QSCeAeawtVna8v2MShIWIJBOTx3PpWrdOrRs8ihs/dU+tZWqJDCVDZMrLyMY/DNS9UUnYg1eO31JYbe0O2QptPHGa5/VNNuZorm0E+Zo1DMp4HHUmthZbizdZwqCXPRgD+lV7i0ulvWkkVnaYMCVP31xUtdTSD5TC0eVkSJ0ZyTgfKBx/nrXTW7hosFzuPzEkVx+qMtjqShOFA5CtgDNamlX6zbCWLKpxwcZqqclax067o6e3kKHZFhsnhiTxUxSR/wDXg+w9qpQ3MeFIwMZ+v41bjuy4GFLsPlGRgn61qhqRVmUlyXjXbjGKBAFEbByfQHAX8qsXHnS/MQBjkbf5VTlmhjyZScL90+vtQ20gcubYnmaAZYxr5+Nu7rxWe07O4XzQI15OCe1R3khu1LQxhecFEORirul29paW7ebkyF9oOMgkjpUSlfQa0HxW8WoGKWGMbTyCON34VrWdhFGhYDzGznB6VnPHLAyAYG9sLjsK6e4tJLXTLf8As+SMzyOvmGT+6OT+OKzWpvFWRXvridFjjiiwjfdJHTHpUFpa3FsNyMJnkcbi/Ze5z7VpthvdunJpFlwrHOOinJ45pa3NofDYlDbmCn5h246GnGBkjBhVFH8I/GnWyrtGCSDlskVKDILraVHlgZVs9eKu7QpTtoUZBcRglZSu75c7QSR9KSK2ZJgEALSHAGMAADr9afeync6lmRU6vnOKS3u1WKSUnBJAXPaq5pdAk9C1DaeRGRG3XA+c5J55NJ9nLIo7qTjBwKjS5V2Q7cL3z3qQXAC9Q3zY9K1inuck3ZlmCZ4tqzHeq88dqsT28NzFlcHPVj/SqMS8EOSEJGf/ANdIUYOkRcopHIX0rup+8eXXik7o0IoEhiGwg46Y5qCWZlmCkYj6tz2p1symJBECAhJLHoasWNjJdETyAeTGNigjIJ611wdtEedKbbuzMu0jcGUDBOORUAiUsqpnaeSCa0JY2e4ZZFwoPAXpRcWi7MoxDZyPpUVFZnVRqWVmQRoSDtBJ7Amqd5Lmf5wMjjA71avZSkQByB1JHasqKFnupJ2ckjGwHsK57aXPSoe87mxakGBxt2k4GalUneyjkAZ56GqccoPABA3c+lToGHIbH19qwmup3w00FjLSJ05pqfeYr3xx71PgKjEY59Ka2D/Dt46gVEWi27kob94AAMgY61sWrAAYJPqaxFJDqSORwc/WtO1ZmUGMjn9K2Rw1kdBaOMADkYznNXjz34rJtsjZ39q1VIZR9a2geVWjZ3BhkGoRnbjOBn0qdlz3IqOMD5sjiiUdTOL0IMZJOCCOhqKRTtbJwf51OwXeCCQQSMetMYZAI2jHPNZWsbJlSTawyecYA4ziq7sUYjJ/AVZlxk4ODnGKoyhd55dfYCmkB87aMt34mu/3RaPS42w0x48wjsPb3r0mxtEtYFWPAVR26moLKzS2hjhhQRxIAFVeBV9FBBIPyjHHavMlK5utB6jBznP4YrJnc/aZ4iMDJb3xWuGGcnqOmO1c9qzNBfs4OFI5A75pQauTPuX4ZNohYYx6DgVLcysfnxgE8jPauehuW3OS4G3IAx0FXbjUIZkjMD7gFya1Yr3Jr2cYY7SVxjJ7VnFAQhZznO5QW9B6mn3F2kojRdzOD83H9ajvSyXQgbLApgN02+1TZI1iLqEapeIqDey5b1xmo7m8lk+dmMcqp8jdvxp1rb+VdOsjOSxCg8CotWmiS42ICxAAyTwDUva5fKrmXNpkU0DTygNuyAT16VzcxltZ2hhPy/3h3x/KteO7EMxilbdwC2TyDn+oouYreXUkS3lVUIy2ehFCj2NVLlIdP1F1ljE0u9yOR7VsSX4Fv50L8Aj7o6jvWdPZQvdILbDowwNvOOeR+dX7zFrEtvEqDCgliO/0qk3YOZNj3uLi6ZoYzlh8wbOOn8+tV1sLm7udhlGd2AM4zWpYvbRW/wBoZ8TYwqj9cUy1miKIzyDzC2WHQAUOOxcW2Xr6FNLs0i3AgIBxwMnqaS0WOdQIyMgcjOAKkuAsqDzOi9+xqKOOOcMH+64wSpx+tFlzG1ODaLskpXytzjcpyMVbsPOcq5kYxL83J71izxpBMzYfKYB75rStLlJXbycHeACGPH1qWludKi7JI0zGzOzM2GGCD1zU8bbomUBfowqhNK8MzQSRsPkDl+xz6U5ZiGUE4xgY7cVKNFqjXgXZGqrhWxnGetP3y7AMjCDv1NZjSOtwOrAtuC+lSNcO20Z2jJxjqKNjKWo27mWIqs3BLZPP6VUikZpNyoiZJzu6Y9aa100jv9oYFMZVV5x/9eoYnlJGYzsOfvc/ma2jbYzvJovKX2rmZXbdkAdMVeBRUHILDjH9axp42I/dMpZju3Dg/SopWkF0EkuPLGPuL/ImuhK+pzVDqra4Ty9pxv8A60saB3IVsk/eYfyrDiuFjBI+ZMZOa17S/SSASEqADjaPWuqMG9jzakXe7LLLI0qRRsETGTxXSQXJj09ECDLDZGuOp9f61zsEyRncfmfqxParNjdyTTlwF+UbUGc4rrpw6vc5JwvsS3sTCWUSSKJUxkZ5P0qvJKB8rjBHTNS6pcFJN0oMs/RQOpY1g3JliKyzNteT5ipPAFVKFwhF3LtxtkQK+Cp5+tUZp0VSsWDjtVe6nAlA3HAwNvvUGyNRsY7XPIJFYThY76E+XQ0IpQ4wp6cn61fgPyDdySB+FZdmPJiHPJ9Kuq4QhfvAdTiuOep6sHdXRddgMDtjsO9RSj1JAA7U6MB41zzg047csrDvwTWcYlKRXMhMvB+YjJ49a1tNI8tV6E881mGNVlZw3HpjrWvpyZj5yf6VtAwrpctzZt02AZbJIrRt2GzA7Vm20bKi5PParUTMk6gD5Sec9qtOzPKqLmRdPGGpvQcjjtSn5lNDYCGtGcqK03HTG4H86ayjIJHPXn1pW5lxwcfnTZGIYkAt3yKxNkVJ8bwByRzVVw24/d/nVl3dwR/FVWWeNGwC1O3YLnn5f92B26CnRyRrGRnJPv3qsLgbRjlR07UiSqwJOAT9BXjtHQWfOHIPyk1j68MrFLg4Hyf/AF6madcshYkdj6mqt26zwyIWxuHrjBqU7NFNXVjKjIa5lIbCsCeen0/I1YtLeNJAijAJ6Vns/wC6KF8t948ZFW45yVj3AK6NuDdzXUrNGFmWY0EZlZiEKHIB/So3mEkiGRQyqwZiR+JqGWXGJGb9yx5J4qy4hjsXibBLHPI5oNY6FHW9UiF3E1jkIw2B93IPrUNpAZ71MOcBSWZxwaatr57II0QoRkgdc+1RuJfL2hvLKnYx6nHepUb7m6ktkZFzbGHVCInbDtkEnOD7VIlqn2hJVy0gYhlLDBro/D1hBPkyy5SNiCOh+ozT/EFnb2MymIeb5vHyjgj1PoapU/duwdTWxHoyRJJmbardsjgZqxd+Q1w+QRwcZx6dKVw128WAEaMY6elV9RtpNhMMisAQck9PbNNqysEbdRjWAkCI2cfeBA68UqaekUoPDqBwTU1pdFlFtLlCozhlyT/hWjbpGZWdysnAOCetXyJq6NoyaK8rgSSSR7wjqF8pjnBA7UtoRGwV1wvXCn9KHUTTCMbcbscGkusQhcspAJ27DwamUXfQ6qTSL87+ZGiq28Hk7qreQsUqyBgcjp0NQ2Eschbzy2xhjKNyfXFTttOF3KU/hY9cVm43N4ytp0L3mPd7SpB25G72ogg3SFnIVieh4x71TikNu+4bQgB+V+4/pUn2uQAOQo7jJyaSi0Dk9Ui9MzRoz/ePUE8c1TlmVgpXh1ByM9c1IZZ2ZjJt8lhwevPeqwUFjtb5c4K4wfqKcUluc0pSZAl8qukZiYsWyTjt6GpZJJZhn5o4ieOev4VXeLZcN9nZSWODuPGKmA5O5woA7nPPtWyaasgSe7LlmsgDeSoK9CzN19cVDdsB5buPmyflGPwqKS6MZVY2BBGcHjA9KzZ5lyCqknOCQchKuDvoQ1Z3ZNNdyrG0cbAPv5XP6Dt0qe21KeBwoEax8YU9T71hXBEreWG3/PnB9TTVDqzOHAbb0Y5C110pWM5wUkeiWk7NAjFgdw3ZzV+2uTCw2nZgZPPH4Vx2gPK8nmvIzRjC/U9q0dUlTCIrN5eclRyW9z/hXXzJanmqk+a1y3Lqxkv5JQAzLwgGSAO9V72/N2QZnJOMD2PtVa1ZBEGZGPU7F7j+grOMI81rqdisz9FByFFCndPU2UIp6l1JXL+dI3bIJ5JNPubqQbBLgsem3+dZkLSDcQwwoJJPUDtVm1kLmHfGWYtjb13HPSsZPYqUdTT0+7bd+8b75ARCMZP/ANatUMrXYUbs9M54HrWTfzG41D5Y9ixjacEZ3d8YrR08MdzkdOF/z+VctRa6HVRm+VM18vGy5GQV6CklwxZlPyjHNNVyAS/GOntTJJCNgAxuPNNI6ItvUkRssFbBC8Z9a29NIZEA6D0rEUgSMy7SvpWtp74baRg9OK05bIwxErxsjoIcHbgnPNSA7dp6bT1PFRRjABJwT8xp9xFvXBJ2kDj8aVtDypPQvjHYdDTZWx0GeQMUqYw3pntTJuhJ6HvV9DDqQZBYFjimysQhIzluKaoJDHHzDue1K/KHlsZzUWLKMrMroApwe47VScx7j5iktV66Kjkkhh3HNZrvk5CZ/wA/WqSFc8taONACHOehOeBUMnCkKxBB9aY9x1wo4zgd6rvOAvJG0c8envXiM7eUdOX6Bjxzz3NVLiUMhEqZz+IqZWjPKuwz2Y9vpTZogufm3g9T6fhUjszL89TINxIUnHtVjzgQgZiSTzjv6Vk6iGTO0H6022vPPjPQSJgMh4yK2pyVuVkOJ1W8BDFNEHXgAE8fWqrSO82Acqg65qjbXUhyGYFVxxjk1ahvHjneQEbWJP0HatGrgrouLIVBkiAV1AODjBrMHl3H2gyt5Ued24dz6VZTdN98qTtzkGqU48yF8EK/HFWgTJLS9ki8xsuykYwAOBSxO93c7SzkvyAzZ/GoVbyp2lEnQbdme+OtQiV3lkMXykADdnBxQ1Y2i77GyWe2vhGkjFVyT83HuPrWg119slIRAmAOvGR2rFsA8rksQZCcnB5rcFsIrYFGxLggg9qaTYN2ZPa2wmkkd1VGU5G0dKWOMASFcEoMsMcY9aks2VLcoTlypyCOc/WoVndRujcpnuB19q1SSVgi3e5DOVgcSoAZD0A6H6VnXXktARHGI2Lbig5LE9ePSrrzoj/vx8udzYrOup98pniKBMYUjvQo3OuMtdCVXYwgQsq4OCGOMVNBJJM2UwiK3IA4ye3+fWsoSSXZBn6MMErV3dKsSBgquP4w39O9KUbHSm7al+QbmIlJBJwMdqmEpVWTYysDgbj1rKh2gEpMzu3OB/j6U7e8oC9Du4A42n3rPk7jvc1I59zupkYEd/6VFKMOmZN2R0J6VShQrcMGZSyj7xycj6U+4ux8iPtLgD5wMBvpS5CZSu9CxNPMWJjQFRgMc4GKijZncGRyuMgSAE4HtVKS8xEQJdo64IHJ9hVR7xmbrtQjIZRjFVGDdiLF1nSMp5kjvu67lxz71DcTO8bIm12I5VTgY/xqq0u4fLI/ljlmboTVR2dAFTGOoxnn6e1WlylOF43Ek1BYlcTZ57Hmn2okmXKnEA65OcD0rA1Gby7tZIS0pz8wJ/pV+1vzDchd2YWXdyO/pz3rdSjHY56kZtaHc6ZL5FtGtvH8q8k56mtAo08W5pAhbnaBwa4+11JiDHHKuT0DE8Gul0+7B07aG3TdBufBHvXZD3lqedO9PUgmupl3QlwMHdI/TI9B7Cm/b0mm2KCFwGORtzSXNmbhs+YqnOWAA+bH97/CoUaNf3Yj8y43cyMMAL7DtUyjyq5dOamy9DM8jBSiqBzt7Me1XYg8UP2gAl1J2kdA3YD+dVoSroI4lzKO5PGK0BiWFCoJAXaB0x6nFcybZs7N2K+nwsQS+T5YBc44LGtuwJBKlcLuyDnORWW7hGjUZCkbnPv15961ISXMZZdo6/j2H9almsS/5m9wQvy5yV/lQpZmwRnByKQEEZyNnQetLHy2QOKcDeLsiTJQbXB54HvVzSm/f5Gcg4qGRA0QyT7e1NBvIJ4PskcbqHJmDHkJg8r75x1961bT0MKrTVzq4ZiXKcnAzzWhbkkHuQRzWTaghdzKCfWtG3Zh7Z79qHoeXULhYqvy4wQSeagml3MFGcN6VJjaDt5A4Ge9MQEt1Geg96GYIY/3WGTk8kU2R9sWOwxjmnuuGIOBnvVa6YYKkY9ulCQXuV7rBzgjgc1lyON54watTnGDxnFZc0gLnL4qrDTszzyS0AIMfyA9x/jVaSLaM+Xu+g6VsseCcHn9aj2iRgUHOOe3614DOxTZzr24Dl2Z9xULtz8tIsaEfISPUBu9bMtr8xGAx6hT/Sq0tqiKeNhPHSkaXOc1FSVwjBtv95a5m9meBy6qu4dx0PtXaT2b/wB4noeO9Ymraaz7ztcKemOlPVFLzKVlqCTMWj53Lg56j2NXYp42jMT5DB/kbOOvrXI3FtcWc5ltiVbupHDD0Na+j6hBfbo2+WQcsh+9+FdEJXRMo2N+OZkjdmLEIccdfrUtpcBypZdyE84rEfcrACXgn0qVblooBHyXU5znjBq0yLEt6pkvEaM7c5GPSrVkFbO8EE/xentVS1nLSqy7XC9PWnFTgmJCu45OTkE1atYd7GrpV0ltdOzbpF2/pW1NJ9qXe+e2BnGfSuOsme2ugzK3lNyR6Gtv7QFi3kBgnAPTOauN7Db1NOJ2SR2JbtjB5z6077TISU8scZ2kjGDVFrmCYIYy+8j7u6n27uy/M33COSeR9faqt2Lg9NRbhAwJushhjkVHbKYwYlUOgOBk8Cpp0Dur5Lg/w5omcbgEQKueec5ppHRCdxrwNGCFXapHIfuaa6h4Q6fJtOOv9PSrXmRcgs2AvAzyKrXEqMDsA2qM9Op+tV1N4ybRSaUxtui2bSMDsRS/bUt2JlkcsOoBypHqfepZLXzYRJtOSM8jn/OKomNoiwXlSOSeCc+tVyItSTRIblDI7jYA3Ifsfent5YhDyjAByDg8+9NiCsqgOrdMEgce1WkmaKLZEAQ3VHHX1qWrF3utDOlYhw8YVVcjk9D/APXqs0jeaxRJJFzgDOD9a0pI1JIb5Dnpt6VU2FMHP3uPu8E0IpQSdyNWlMm7a5H8QPT2470s8IzkvliM4RDg+2at4BRShU9cq2SxBqOR2WP/AFki7ecD+L2FZyd9BzfKroyb2NY5VDqIwRyidW+pqhNaruDlikY9+SfQVoXOST5WxMkYJ5Y+oqDgFQ2GHY4/lWkXY4qmruW7KaHYEVtkuOvqPrVi1V4VZwxkk39f8Peq5KSuI1TdtPDKvIqyoEMeNwDgZGP89a0VTscs4XLhvLmKQtcH5+y7q0rEiULwGLDp1zWBBIWlAIBYgHjpW3p94bQuyxb5T8obpsHoKcpX0ZPJy7bmtNvhk8ksFc43bBwParcErxqvIz0GDWVbq0sjSTE4bk4HU+1SSzFrgYUjoBnuPpUbmkdtTQRlefayZCncF9TW7GwwoUdiP8a5+wO1iZN2M9q2oyQABgnqalrU1vqrFvJ8w7uM/p7VcgA5Y5GO9ZcZZmCk/d61qWqqyAMa0irDlOy1LKKzMOhGMVo29ucA7ssRycU2zgVUyeauwAdce4qra3OCpWvoWLdcLt7/AKGtC1B8sEjJPNUo2QsOCQePzrQjxtxjjFM5ZyuOLYGdoOetMXsSSe+fWkfnOev86Y79fQ9qZncaWw5Oc1Uuemeh7k1I7ZBAOGJqpcvhec8c/WhBsUrqUDdt55rLlTzH3NyT7VcmcmQ5/GoHPPAz65q+Um5ywjLAYUEZ4JPSpSoDBWQbhxkYqwI3XaCAw+lSY2qP3X44rxeQ67spSQIFIXhgetVrmBgUxjLdCB1P0raWMMuSuQe4600xKFPAB9CKj2fUpTsc+bUyNyuQBz8vWsm8tW8sjYwGOAvOa7Py84yFCkelV57MOucAkdKTizWMzzfUdISWIkHBPTiuN1XRHWUSpvSRD8rrwRXtc2mCTk7iPQnj8KxtQ0cdGX79JLldzTmT0PJItamt3EGqxkcfLMOn4+lbS3UcqJJEiuMDnOc1p6x4bLIQI+SOnWuKu9GvtMkeWyZouclDyp/Ct4yTJcTqkQLciWOMAHqgpk0m9gPm2k5rmLTxK1tIqX9v5BP8QyUP9RW7BdR3Ee6JkkR/usOf1rXlsQtDSt7oOHjHz9xn1qUXAdtiAofTtms1GO1zjLA5DLxToL1oWDhCVYZJPatI67i9DZiZQhYthgecHtVpbsFSegPBBrJDll+Y8EZyB1zUqyeaQo2kjnpg1SKTNZrl26Mc7ckNzj6U+2kfzG/eLwBk8cVmq6htrjb7+tW90YZAVYn+IdRjrVo0U1sXm2SuUYquT3IGT71HFGZYTkopHHJ4J9KrBkUKQp2YyV6jmrcM+4YGCqnuDwKaRrGbWxMtzJFbmP5AWGAVHUemKq3cY8rMbDhdu1Rzn0qzczLIYn2KNnqcAn2qrcORKcchjzt6U/Q2hPUpGMMin7gYfMF9aLd/LkfEj4Xu7dfoKnuTFGNpIL4yF3df8+tQ3abmzIQvsOv50N3N4TVrDDMxLBn78umMCnCZ/K27sxMe56H2qqIgytIDwBjAH9Ke5PlAKMoSDjPQVLTNVVT0JSzMBt47HdwCKHbAPlvsxn5u+Pr2qCTCbBsbpkZ9KjlyCp27iem4569sVDj2MZzbKsil1LYXBHzY5/X1pjRJ5YIZmPYfdUe571NllYiUfLxkA4NSeWpKeaGC9yBjA7U2jB92EUR+zEq7bV64PLfQVG8bLLJGGORyR7+5qeFQqs0TnGepHUU+BmefbgOWwMDgD3+taxSRg3K/kSWcbQRksDk9B7D0rQgLyOjSnCGo4bdWKkl2Xtnjmr5jAVCiBg5+XnjAqWhXu7ksabQR1IPBz/SriLuZZJBG23p/+uq8Nrhw8hO30BxxVo5KkjG0HjPFSNO7NSGVBEox/SptwQk569T/AEqgksSgBl+bAGfSprVjLLypxngY6VUY3eocyiatlGXbkDFb1nb7UAI6H8Ky7ZCuNuMfyrahbC4B6961aWxxVq7eiLaHamBjH86ns1Z92R8vPJ6moLVcnABbsa0bdBtxu59fSntoc7nZak9tEpI+Xp3PrVncO3Y8mokG0EdqcPu8HcKLENisMcnOR6+tVLl9uBmp3baAOp5yBVGWTPcAdqYr6jnYgAjv+lZlxJnfntxkmrEku0ZxzWdLkJ8wyxP61UUJsjYgntx1qB3YN8uT9KexyeOe2B1qIyAcECqJ5rGftVioOVJ7A81YSMdFLD2qCJCxJ49uMY96sJnAOFwOeDXjHaKkRAyCfWnsuFywzUqbeGJO70ApxVCM4AXqKoRSILHG0j37U10+UKMkk5OOgq8I9qnC5+hpCCxIwBikWmZslu6hQuWwahuITIcPH1rZ8kBDtORnv1phTOThST1Jo5L6FKRzV3ZxuNoTJPGPasPUdDjkXI5fn5etd1NB5kRUHYf7yjkVVaxUIqks2e560ez1NOY8b1vwqrJlYt/XORXD3fh+60+Vm02SSBs54OQfqOlfSdxpMcwJwct1yaxr7wyk53KqqDnrVR5osTszwW18Qahp4Mep2/mIeDJFwR9R3rd07WrK/AWCUFh/B0Yfga6/WvBjbSfLBI9K4TVvBjEk+Vhl6MvBrVNS3J2Ojd2aLaNoz0GOcU1Nsapk85yCK4TZrmlPiGYzxjjZN8w/PrVyDxaquE1OzlgP99PmH5df51fL1QKR2guC5BHzdc89qsLdqvDsf90isGy1Wyuv+PK4jk9gcMPw61eRiAS6lj2NNNopG2HaRSSflI7dqWKeVJOTiM8kLxWXbzMrbZA2PXpV0EFsrggdVxVXGptaF+WcSphyowOg5496ISgCqG+8MkDqaosQAxJ+YYOB6U8XGFBk5UdhwKu5ad9iWRhbzLKsY3BcDPINVJLl3QuRGnoR/hSPcxxyiTnB6qTmqM8nnpnGDnIJ70kdEJkjSSzHD9F5DEcfSp7c+Yccgn0OSaoIXgxhvl7ipAxTBT5e5wM5P1odma83mXJpg2wEYI4bk5H4UbowwEaM4A4P9cVXhK7SHYlSOmef/wBVOeRQpVGPBzyP60tjOV+o4lw6s8eMnv3olUbzgEc4wOaiRJBEX3rz684oM8mMFmLdjipdg3LEauTtRNqAcnFW4Y44ZQy5aUntzxVT7QflHJb0zViFnJYpGVbHJ9KWqM5N9TUiV0jDu+wNxt65+gqW3DDLbRg96zopiqAFmJ7c1OJiTlmI5yoz0pO7IWhrBtwI3cnqTxTjJnCRqrsep6Ae9UbeOaQqEDnJ71uWOnqQvmEux5GM4q1F3MKlaMN2JbWQkkyzFwB16Vu2VuibQEJUcg9KW2tMbckL7VqwRKnQD3OODW8YWOGpiXPRDoIAQCqnbWhDApA3DHbPemx/Lggk544qdWJz1+mM1VjJPUtwhIowQoPtirMTt1PHPAqrEM4O056ZzVhQAcAn8aVirlkHPKk/Wg4VeRgDrioWbBHAH05obe5wOSeTxQAjPkEgEEnvzVe4YLj5huA6460SyEMSM+1Urp92AeQOpppEtjJZB68L3qpKwOBjGT1JoLcYP40wfe5wOO4qkS3cG/dt7ngD/wCtULAE/dJ+mKmbDEBfTINRsVU4yR9P/wBdMFYzg67xgjpUwwyqMnGc4zjNRFMDtmnJ91cAA9eleMd1y2DhR91cHtUpOBjBIqiA6z7yxdMfdx0qdZC2eMY6YpphYtIwbrwB6VGrLKx2ochscjGacmD3zngc96mYZ6rkjvTsNMYMFfm4ANPCgsCPxpysOM5Pcgil3qhBYgZ7n+VXbqCkMMYLEdvXPak8kHO7aSO39KnU9aVfY5PpTsVzFYW6EENle/HamtaKcbSefXnFWejck+m096UkZ6cf54q1qK5mT6b5i8OM+uOtZN9oTyqxwjDHGV5zXWhPbkjpTCmVyc+2aOVMLnl2p+EWmQny0PPb0rjNY8EznJWFWHYY617/ACRg5BABxVWexR0wAKpKwuZ9j5U1HwZLHI58llcc8cc1RiTXdMJFtdSlVP3JBvH619R3WgwTg7kUr9OawdQ8HW8rM2zA6VauJzaPB4PFGoRNi909ZexaM4P61pW/i/TiALgXNuepDR5H6V31/wCBR85RBweoFc1qHgWTOFTdnuKrlv0F7XUhh17Tp9piv7diOMM20n86srKJ8sjK+AOAQR9a5298IsAQ8GB0GRzWQfDElu7NF5iMRxtJBqvZoqNY7h0brtP4jg1E7DncMdvpXGpZ6pbttW/ulA+7+9NTRtrSDC30rcH74DUvZs2jiEjp3lAC5ycDrmnrcOItuQB6LXNC41oFcyqV75iH61IL7VFYDZbkHo2w5/nS9lIr63A6KKSNgWODjpT1YlGUNjB5Fc6dS1ZiNsFtnPdTz+tTxXmpNjzYLYj0UEH+dP2Mh/WoG6fmGASQKVVdwNoz7YrOibUZW+WCJSfu5Bq19g12YL5UkUOQeRED+HNL2UhPF00X4UYEn+Ec9en1q/AZnVUQkoOcCueXQfFZf91cpMFPR028/hxU8Vr4rtv9ZpiTADP7qQc/gRVKgzCWLutEdPbWUsgUIpX/AHh3rTtNKIcSFTkdjXJ2uraxGSs+k3AYDJAxn+dacGt3e0CTTr9B0/1eR9OKuNJI5Z1akup2trbJEBlVPrklq1YAqKp8wKv90CuNtdZnaPmzu/oI85rds7i4mAP2S59gY8fzqrqJg4t7nSRMqj5ePcCrKBic5GPpmsyzSZsfuZV+qnitm1gkUElQc8/MDUuaKjB3HxkDhQT9DVyJWYjpg+tKkZAAIbpwBxVmNVBBwRgdKXMaKPUEYDJ4z7dqeTyNoP40Myrknj1qKSYiItEC3OMbsZppBfUnaQtgHqD2qN5gAcMcZ6U15BgZyfaqpf5SeMDoKZm30CeTdjBOT0FVZWy21c8Dj606RyVBBy3XNVnJUsWwT0HPeqtYljeW45x61MoAzxToozty31wKkKdO3qaBIg2kc59qpTJvkJJ/8dzWhLwrY9eeaoSFQ53cmmUUzwFBJyD64p/8J4HHemAgAZxj0zTjudwqbdgHJzivI0O0epZlIVsDHUDpUidBjsOtRj5eowfY0sbbMg5Oen0ppAWUIAyckU4SkAgndntUAfJ6knrTyQR159fSn1KLAJAJyQT+tSNtIAZVb+LBquGBXIz+NSE46ccVS8xBdX1raRebd3EVvESFDyuFGT0GTUsUvmBShUrjOV5BrmPG3hW08W6KdOvnkjUMJY5YzzG47+/WpfBOht4X0KHTftk95HGTteb72D2HoParS7iex04bPFOPJxwO1QxuCQT+I9Kdn1GTTAlwcnA5/lTumehqASAghWx680+NieQMD1FNASgbh1BzxQ0IPB+tLGwBxx6cU7JJODiqsFyLyh3OPTFNkgIIBXipVJHDA1KRndnAJ6DNWgZnTWSv2H41Sn0iNs4ABNb3lgjjB4qORBtxjIq0S4pnKXWgwyLgorH1xWRdeFrdiD5eD613zQKR8pyai8gEDKjIxxVcxPs7HnL+EYJCSY1b14qhceCovIIiJU/SvVfIAzwetQtaq5Ybc471SkkQ4M8mPhWOPakinGMZxUTeFUfOIyVz6elesS2KtlACc9SOmKrfYVXhRyOlUpXIcWeZR+FomQjZhxxT4/Cu1xlPkA+8BXpCWHzbmANSrp6EgHkd+KrnQuRnEWmgpC27aGbHfnNbMGnKVU7E+mOprpEsUjcAqOmKkeyGVK/iPWnzqwchkJpsYChUUDvxxUx0xWIIXP0FakcJBAI79qnW3wxKlgTyf8KlyGqbMX+ykcZ2ZPTle1TLokTAbEAxW7GpHUDB4znrUqIMYU4wcc1k5M1UDFh0hARkZ9jyKuw2ESgDA468mtMY6OoCj0oMSsPlwR7HmsmaKy3KotYwrcsvp7/iKfsdVBaYdOAQf508q6Z5z24FCbehIz6ZpJdRtqxE8zrywGfY5qA6gjMBuAb0zj9KvtGuP4WB9RzUL2cLkZQk47GrTM3Yqi7V2ILfrSrIm7k59BinvYw9SSh9KY9gFP7qQ56c81aaMpaA0mBx6f3qiAznJAHcGh7WVF4Iz6n1pPJkU9N38qpE2EbBPTj0NR8O4Pp0pG87uAOeuc06OJ1HseTxTYrXZYGMFQcsO9IzDG7gDv71BtlO7Hyg0pB7kkDrg5ouCQkrqPcZ5FZV1cIJiDk1flI57c8/Sua1O9jjuiu3PHeqQmjT3IR7inFAVBHOTyOOlR8Hr6euKdEApwvfivJOzZEhIU+vHWkOwr0FLyGPYd6Qp8oI5ppBcEHIyTgipRznPX2qIKUIyMU5GPYgY75pWHclHBXjr1ApGLcFcgelLGzDBx19OakyGODgUxtiISTlgQffvSTSiNuvbtS4LDkN9ajaNjz0IHf0qrkrcel0obk8dQOlTpOr98AdvaqTQ/LwcH3GKiKlGBAJ9cUXKSRoSBTOJF5Y1ZSQNkDH41nRz7iFIIz/AHhV0Nheep64qhE4kUAAZ/E8ins4AGT+IquGyPmAZQO3UUAjaSCD6BqpCuW1kz749aerj8PWqBbAOSRn9KkWVgcYJxWidiS+rg8jODSKABgd/X1qsJRng/lUiyDHHf1qr3GtCfAbGBil2qenFRRufT6Cl3HnB496Y9xzD0AJpjRK2AQPwOKkXeeQRnrxUjclTnBx2FFwIRDtABBA7cVE8McnAPAHWr5UADGPpSMqkgDOSccUxXKUduo6/d9M1IIMD7vFWnVf4gB9KTaue2e9AN3KwjQnA60qx7csRweuKtKh28YpWTC5A60XYiBUXYMkE+1NdMADbweKlCBj8/GfTtUhRvl2/MMU7jsVmjOBjOD680q88Mc/0qVR8+Tx7GpSo49c9KQ7kI4YqM59xQjKGAwc0skDBgysVPbFNDsfvDLe1K1xaFgqeDwR9eaa0aOD6/rUTFl5TJHcegoDg8sCp7UlEQ0xSoowcrnpimJMGOD/ADq2ku0EAhkIOajkijdsYwen0pi0e5WkYk5fA+tRgqCMA5x+dSzQEj5myo6etRSFVYjHQdatCaHKMsC3zZ6c012+8RyDwfamtIGyRx9ag3Zyc9ulOxk7Cq5yAcY+lK0m4FRnH9KYoJPTmkUfePr29KYtCQOABg4AHWkc/MegyM1HtznkYxwKhUGN3ZmLFuR9KBXRFdyqitznHX3rznxJqyQamyDH3Qa7TUrgJC5JwFzg14L4w1+OPXJg8gXIyO/HNW9Aimz3sx4POOacvC8DIHfrUh+cZyCRQsXA2kYHpXlWOtOwkYJycYqQZH1oKEMOhoKEjJ6e1OwgAxnGKQrnjHPXmnRxnIJB4qcp3HSmkwbsV489V4Pv1qZcFhjqB2pAoLcfKT7Yp5jAOcYI5zTsO5JnJYMOaTAJz2PPvS7ckEHB9qMcgnHFOwgMY4IHTn60mwtk1LxgDjJpyBcEDIOOKFGwymYj3GMdacEYMCrEY55PFXdmW5HXvTQnzfL265osO5WL7SAwwx5z2pwxnoRmpnhXPTmmNHgZXqO3aquIjVwflbr3WpQSqjHA6VGVLDDBT2IamMjoCVbOOx/xq73FYkLHdnvjt3qVZcKDn5aqeZwd4KHtxkVHuwchxt+uadiWaLT7VyOAO45zUyTZAORtrJ88xyAN3HboaeLhQeGFNXHc1vOAJ7j1HSpEucqOM8dBWOtwRjnp+lSpNxyQfQihsd7GpHMF4545OTTgxPJyW+tZgkwMls1YilzggnNUibmgDznP4elSDg4znvVOOQsRuNThhj5iD3OetMLlqMhlG/n3pzKpGKpNICOOGz1HSiOX5tpOOaALTdwACPemkFWBUkc9DUaSc46+meKVXx95hj+VAuYmlJP3lBPrUYjKkFTxjo1IXwMcAZ61G0qnlTz/ACpoV7CyOVIByPc047W5U54/OoTNkfMPzqPocK2M8gUWKJ24GRn0+lKGVmBwc+38qrCZl46UGUnpx70khErLg7lwM9vSkFz0EgIx1qGSQjkk1GZNww3T3pivcuCRfmw4IPv0qNthwCcdsdqpsQSCCOOiimM0gGVYD29KpIhkk0BBJjJ2nng1EyMrfK3I6jFSLIxzlR2HFNlwxAGQT3FOxN31IwJeDkU3E3oOelTHpxwaiMnB3E5FNCbE3SAcDn0qnc3LxnDLzjk1bEoCsS1VLmQbckK31q1cjmRyHivVYbewlUNhip5NfMfiWRtS1q5mAcqrbFwOw/8Ar5r3T4r38FpaO7LyEJ614lY2ztbhupJJJyOprOq7GkLWuj66X0HfvUyNk44xVZWAJxjn1qUtx8qke9cJvcnDAnGcZ6ZFPIIHXOarqMt1yQam/iHGaolseGIHTv8AWn5wwG0+uajwQF568VNtXA25yOlILhtJHByOvNJg5I4/z3p4OOqjpSK2CcAj0qkhoI8Ac859qXsc9qUnpjpSZ+boelML6j1Dde4oU+h596jLdx2p6NyDjk0milIkVuxzz3p4fCjOc1CORxk09ckHAxQFyYgHGOO/1oK8c4H1pitipUYSL05H5mm0F7DCM5A5x7VCYyO2farSkMoIBFIp55IApodym0KMctw3ZulRSRNyCqOPpg1ottYdKj8sDbuwO/Bzik7orcypIgqhQHUdSG5FV3iZSNvKdu4/xFbbRhjnqp7dqZJCGxwMelLmYJGQhc/MoDH/AGTzSAyKc4bPUZHStR4F9z+tN+zck7g4x3o5gsinHO5PQ4qxHOxGASR9KnEXd1wep2nNOEKuMDAzz0qlJk8qGRzttIzxU0c3HB4780wQAAYAx6AUoiI7H6U1Ilom87JI4AHvyaejbiQP1qERlTnHHXipEOD8wI+lWpdBFnn5SuAM96MkBuQT+VMXIyF+7nNTKvPPI+lO4ETFj0Oc9qad5bPO2pmUZ3LlSR2owSpOACOnvSuHoQlmGcDJPHNDKSuAQPSpHB44wKaRyMcj19KZFyJgVUZ65zx0/Co2kJJOM89TVkrxyAfeo2jB4UYHoT1pphvuQeYSw569j2pztnGBkHj2p+zOc/p1pSmF2gcGncl6Ffy885pFVj94ZOelWFjweMelKVGDnnFNCIkI24Joye/anMVZu2DVeR8MACPxqlsS2SO2B1zmqcsq7SXyFHf2qO5uSg7gVU+0guFIOMFvaqSM22WJCfLXaOe+azr6SWKMsSCwHrVprlNvPauV8ba7BpukXE7sAEU8irSGm0eJ/FfWGvdYWxRiBnc4z78f59qxLcDyhuTJ9V71zl9fm+1We7mJzIxIzzgVPHdSBfkkAH1rlqrmZrbSx9iqcDv9cU8SEKecntVdMox5yKcnLkdO9c5orl2N8ggkn39amRtuD+lVYhl+pxjpUiseNx3ZGeaNBPeyJw5ycHkdjUqsCMj8arI+WPqKmQfLuyevSrduoWdibJ6DjBpd3QGmKMnr0pCxVyDzgU0gJPbnilHA5pi9MjjtTlBzjPX2pJDFHzH7pHvTipz3x60oP6Ur5yBnrzSYxAQKVn2j9CBQoDY7D2ppGBjr1oGV4NRtnvJLZZczx43oRg1oBtvOO1VRFGJd+xfM6b8c1PuPXnPehJ21G+yJd3pxRgOGVhkHimopOcn9KVeOlHqOzQ7YM4APHHFLg9cZNI5Kt9acp2nNIeo0JjgDH170rKrYB9epqUjgeh60HGGYDGD60DTbK23AwMgg9qXB9OKk6lhnjmmLuz8rYBwcEZpLcA8tSRux+BxQYiBlWKU/naSMce1OlZkCgH86pa7Cd0RbJF9GH15pwKl9vQ46EYpu4HIYZ9xxipV5UAHgjPPPequK1wWIfezn3NKASvAyKYpJDA9hmlJIBYGrsJ3RMoAXgdOaFkHXkHtmq7EsM5PSoy57HHFMzdy2WAzzyOtHmfMOgx71U80hfXtTPOY7RxzT0J5i8JAcjg+xFI+0nOSfTiqqyE8EdBUaL5ZYqWy/Jyc0MEXNwxkGo1JEpJOQRx3NMZyRj+tV/OY5JAOBiiwXNESfLkcEelRGUZIOM9eKpGQ8n37U5GJyM++apWMnIsLIQRnjPemTE9jgeuetM3H6g+tNkbBPGSeapNA2NZiD3Jqs7cN/CewNSy8856Y/GopOnOenrTTRDZWk+fBcZ+oprBQORjmnFsnjj6VGSchc9eSavqJFW9KKp4NeC/HHxBGzQ6Tb/fPzzN3A7CvaNavHgtnkwCRk4r5I1/UJtV1m8vbk/vJZCSM9B2FDdol07tlGNSzACt7T9Nurm3328LOmcZHTNU9Es1vL6GJmKqxwcV734T8N29xpZ8uQxJG5QKFz2B/rXLJ3di6lRR3P/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When the overlying skin is thinned or necrotic, the best procedure is incision and drainage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Breast abscess with skin necrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When the overlying skin is thinned or necrotic, the optimal&nbsp;procedure is excision of&nbsp;the necrotic skin, which allows the abscess to drain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Incision and drainage for breast abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large incisions are not necessary to drain breast abscesses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Results after incision and drainage of breast abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Results one week post incision and drainage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_8_9354=[""].join("\n");
var outline_f9_8_9354=null;
var title_f9_8_9355="Stillbirth support PI";
var content_f9_8_9355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Support groups for stillbirth",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Toll free number",
"       </td>",
"       <td class=\"subtitle1\">",
"        Web address",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Compassionate Friends",
"       </td>",
"       <td>",
"        877-969-0010",
"       </td>",
"       <td>",
"        <a href=\"file://www.compassionatefriends.org\" target=\"_blank\">",
"         www.compassionatefriends.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M.I.S.S. Foundation",
"       </td>",
"       <td>",
"        888-455-6477",
"       </td>",
"       <td>",
"        <a href=\"file://www.misschildren.org\" target=\"_blank\">",
"         www.misschildren.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wisconsin Stillbirth Services Program",
"       </td>",
"       <td>",
"        877-216-8535",
"       </td>",
"       <td>",
"        <a href=\"file://www2.marshfieldclinic.org/wissp/\" target=\"_blank\">",
"         www2.marshfieldclinic.org/wissp/",
"        </a>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_8_9355=[""].join("\n");
var outline_f9_8_9355=null;
var title_f9_8_9356="Cryosurg BCC advant disadvant";
var content_f9_8_9356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cryosurgery for BCC: advantages and disadvantages",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Advantages",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Relatively quick office procedure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Requires little (if any) anesthesia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Does not require sedation or general anesthesia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Offers good-to-excellent cosmetic results",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Offers excellent cure rates for primary BCCs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Can be performed on large superficial tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Can be performed on multiple tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Can be used on BCCs fixed to cartilage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Can be used on BCCs located on the lips, eyelids, nose, ears, dorsa of the hands, scalp, trunk, and extremities",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Well-tolerated even by medically complicated patients",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Disadvantages",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Creates an ulcerative wound that is exudative and requires active participation in wound care",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Commonly causes long-lasting pigmentary changes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rarely causes nerve damage, anatomic and functional",
"impairment (ectropion, stenosis of the ear canal), alopecia, and tendon",
"rupture",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Requires a great deal of clinician experience in its use for successful outcome",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_8_9356=[""].join("\n");
var outline_f9_8_9356=null;
var title_f9_8_9357="Gene switching in Borrelia spp";
var content_f9_8_9357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    Switch in serotype Y to serotype B by a relapsing fever Borrelia spp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 192px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A serotype Y cell with two linear plasmids. The one on the top bears several different vmp genes that are silent. These are vmpP, vmpY, vmpB, and vmpG. The second linear plasmid has a second copy of the vmpY. It is at the end of the plasmid and is expressed off a promoter (P) at the site. The serotype identity of the cell is determined by the vmp gene on the second plasmid. In the switch, one of the silent vmp genes on the first plasmid--in this case vmpB--replaces the vmp gene at the expression site on the second plasmid. There is no loss of a silent vmp gene during the switch. Now that the vmp gene is replaced on the second plasmid, the cell's identity is serotype B.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alan Barbour, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_8_9357=[""].join("\n");
var outline_f9_8_9357=null;
var title_f9_8_9358="Contents: Pain: Assessment and management";
var content_f9_8_9358=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?34/55/35709\">",
"       Palliative Care",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pain: Assessment and management",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pain: Assessment and management",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/58/7077\">",
"           Assessment of cancer pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/59/16312\">",
"           Definition and pathogenesis of chronic pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/1/19477\">",
"           Ethical considerations in effective pain management at the end of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/22/40296\">",
"           Evaluation of chronic pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/41/21146\">",
"           Overview of cancer pain syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/49/42778\">",
"           Overview of the treatment of chronic pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/37/12890\">",
"           Pain assessment and management in the last weeks of life",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Specific pain etiologies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/41/41622\">",
"           Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/27/6585\">",
"           Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/8/36999\">",
"           Management of bone metastases in advanced prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/8/33924\">",
"           Radiation therapy for the management of painful bone metastases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/21/26970\">",
"           Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Therapy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/7/30842\">",
"           Cancer pain management with opioids: Optimizing analgesia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/4/9290\">",
"           Cancer pain management with opioids: Prevention and management of side effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/9/39066\">",
"           Cancer pain management: Adjuvant analgesics (coanalgesics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/43/43704\">",
"           Cancer pain management: General principles and risk management for patients receiving opioids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/38/21098\">",
"           Cancer pain management: Interventional therapies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/24/4488\">",
"           Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/26/32170\">",
"           Psychological, rehabilitative, and integrative therapies for cancer pain",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-8EFDA43CAB-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f9_8_9358=[""].join("\n");
var outline_f9_8_9358=null;
var title_f9_8_9359="Noninvasive carotid tests";
var content_f9_8_9359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 585px\">",
"   <div class=\"ttl\">",
"    Sensitivity and specificity of noninvasive carotid tests",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 565px; height: 358px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Blakely, DD, Oddone, EZ, Hasselblad, V, et al, Ann Intern Med 1995; 122:360.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_8_9359=[""].join("\n");
var outline_f9_8_9359=null;
